Aemetis (AMTX) 10-K 29 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 29, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000738214
Entity Registrant Name	AEMETIS, INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-36475
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1407544
Entity Address, Address Line One	20400 Stevens Creek Blvd., Suite 700
Entity Address, City or Town	Cupertino
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95014
City Area Code	408
Local Phone Number	213-0940
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	AMTX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 253,200,000
Entity Common Stock, Shares Outstanding		42,608,698
Auditor Firm ID	49
Auditor Name	RSM US LLP
Auditor Location	Des Moines, Iowa

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,667	$ 4,313
Accounts receivable	8,633	1,264
Inventories, net of allowance for excess and obsolete inventory of $1,040 as of December 31, 2023 and 2022	18,291	4,658
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Total current assets	36,400	18,136
Property, plant and equipment, net	195,108	180,441
Operating lease right-of-use assets	2,056	2,449
Other assets	9,842	6,088
Total assets	243,406	207,114
Current liabilities:
Accounts payable	32,132	26,168
Current portion of long term debt	13,585	12,465
Short term borrowings	23,443	36,754
Current portion of operating lease liability	406	338
Other current liabilities	10,302	8,474
Total current liabilities	84,389	88,281
Long term liabilities:
Senior secured notes and revolving notes	176,476	155,843
EB-5 notes	29,500	29,500
Other long term debt	51,717	11,678
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,200	116,000
Operating lease liability	1,783	2,189
Other long term liabilities	3,329	5,477
Total long term liabilities	375,994	320,687
Stockholders' deficit:
Common stock, $0.001 par value; 80,000 authorized; 40,966 and 35,869 shares issued and outstanding each period, respectively	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities and stockholders' deficit	243,406	207,114
Series B Convertible Preferred Stock [Member]
Stockholders' deficit:
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 0 and 1,270 shares issued and outstanding each period, respectively (aggregate liquidation preference of $0 and $3,810 respectively)	0	1
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Current liabilities:
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current	4,521	4,082
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Long term liabilities:
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	$ 113,189	$ 116,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Accounts receivable	8,633	1,264
Inventory Valuation Reserves	1,040	1,040
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Property, plant and equipment, net	195,108	180,441
Operating lease right-of-use assets	2,056	2,449
Other assets	9,842	6,088
Accounts payable	32,132	26,168
Current portion of long term debt	13,585	12,465
Short term borrowings	23,443	36,754
Current portion of operating lease liability	406	338
Other current liabilities	10,302	8,474
Other long term debt	51,717	11,678
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,200	116,000
Operating lease liability	$ 1,783	$ 2,189
Series B Preferred Stock, Authorized (in shares)	65,000
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	80,000	80,000
Common Stock, Shares Issued (in shares)	40,966	35,869
Common Stock, Shares Outstanding (in shares)	40,966	35,869
Series B Convertible Preferred Stock [Member]
Series B Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Series B Preferred Stock, Authorized (in shares)	7,235	7,235
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Series B Preferred Stock, Shares Outstanding (in shares)	0	1,270
Aggregate Liquidation Preference	$ 0	$ 3,810
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	113,189	116,000
Variable Interest Entity, Primary Beneficiary [Member]
Cash and cash equivalents	1,093	165
Accounts receivable	55	165
Prepaid expenses	1,438	858
Other current assets	289	725
Property, plant and equipment, net	81,966	71,633
Operating lease right-of-use assets	145	224
Other assets	4,881	3,458
Accounts payable	3,815	9,192
Current portion of long term debt	190	0
Short term borrowings	9	19,831
Current portion of operating lease liability	48	41
Other current liabilities	0	645
Other long term debt	40,857	31
Operating lease liability	67	115
Variable Interest Entity, Primary Beneficiary [Member] | Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	$ 113,189	$ 116,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Cost of goods sold	184,700	262,048
Gross (loss) profit	2,017	(5,535)
Research and development expenses	152	180
Selling, general and administrative expenses	39,266	28,686
Operating loss	(37,401)	(34,401)
Other expense (income):
Interest rate expense	32,995	21,407
Debt related fees and amortization expense	6,524	7,363
Accretion and other expenses of Series A preferred units	25,313	9,888
Loss on debt extinguishment	0	49,386
Gain on litigation	0	(1,400)
Other income	(2,077)	(14,340)
Loss before income taxes	(100,156)	(106,705)
Income tax expense (benefit)	(53,736)	1,053
Net loss	(46,420)	(107,758)
Other comprehensive (loss)
Foreign currency translation loss	(219)	(1,102)
Comprehensive loss	$ (46,639)	$ (108,860)
Net loss per common share
Basic (in dollars per share)	$ (1.22)	$ (3.12)
Diluted (in dollars per share)	$ (1.22)	$ (3.12)
Weighted average shares outstanding
Basic (in shares)	38,061	34,585
Diluted (in shares)	38,061	34,585

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (46,420)	$ (107,758)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation	7,660	6,410
Depreciation	6,933	5,535
Debt related fees and amortization expense	6,524	7,363
Intangibles and other amortization expense	72	46
Accretion and other expenses of Series A preferred units	25,313	9,888
Warrants issued for working capital agreement	409	0
Loss on asset disposals	0	47
Loss on debt extinguishment	0	49,386
Gain on litigation	0	(1,400)
Loss on lease termination	0	736
Deferred tax (benefit) expense	(750)	832
Changes in operating assets and liabilities:
Accounts receivable	(7,422)	294
Inventories	(13,843)	360
Prepaid expenses	1,838	1,777
Other assets	(2,016)	(3,941)
Accounts payable	13,726	2,183
Accrued interest expense and fees	23,558	15,501
Other liabilities	(1,757)	(10,125)
Net cash provided by (used in) operating activities	13,825	(22,866)
Investing activities:
Capital expenditures	(33,119)	(39,157)
Grant proceeds received for capital expenditures	9,432	7,851
Net cash used in investing activities	(23,687)	(31,306)
Financing activities:
Proceeds from borrowings	75,482	69,356
Repayments of borrowings	(56,130)	(26,266)
Lender debt renewal and waiver fee payments	(1,681)	(1,169)
Payments on Series A preferred financing	(30,000)	0
Payments on finance leases	(428)	(481)
Proceeds from issuance of common stock in equity offering	21,718	11,987
Proceeds from the exercise of stock options	133	206
Net cash provided by financing activities	9,094	53,633
Effect of exchange rate changes on cash and cash equivalents	49	(213)
Net change in cash and cash equivalents for period	(719)	(752)
Cash, cash equivalents, and restricted cash at beginning of period	6,999	7,751
Cash, cash equivalents, and restricted cash at end of period	6,280	6,999
Supplemental disclosures of cash flow information, cash paid:
Cash paid for interest	9,813	19,515
Income taxes paid	20	10
Supplemental disclosures of cash flow information, non-cash transactions:
Subordinated debt extension fees added to debt	680	680
Debt fees added to revolving lines	0	800
Fair value of warrants issued to subordinated debt holders	1,278	1,939
Fair value of stock issued to a related party for guarantee fees	0	2,012
Fair value of warrants issued to lender for debt issuance costs	318	3,158
Fair value of stock issued to lender	0	1,335
Lender debt extension, waiver, and other fees added to debt	0	583
Capital expenditures in accounts payable	7,900	15,411
Payment of debt added to revolving lines	0	16,266
Operating lease liabilities arising from obtaining right of use assets	0	306
Financing lease liabilities arising from obtaining right of use assets	0	2,932
Capital expenditures purchased on financing	$ 0	$ 290

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021	1,275	33,461
Balance at Dec. 31, 2021	$ 1	$ 33	$ 205,305	$ (321,227)	$ (4,350)	$ (120,238)
Issuance of common stock (in shares)	0	1,885
Issuance of common stock	$ 0	$ 3	15,530	0	0	15,533
Series B conversion to common stock (in shares)	(5)	(1)
Series B conversion to common stock	$ 0	$ 0	0	0	0	0
Series B conversion to common stock (in shares)	5	1
Stock options exercised (in shares)	0	296
Stock options exercised	$ 0	$ 0	205	0	0	205
Stock-based compensation	$ 0	$ 0	6,410	0	0	6,410
Issuance and exercise of warrants (in shares)	0	226
Issuance and exercise of warrants	$ 0	$ 0	5,096	0	0	5,096
Foreign currency translation loss	0	0	0	0	(1,102)	(1,102)
Net loss	$ 0	$ 0	0	(107,758)	0	(107,758)
Series B conversion to common stock (in shares)	5	1
Balance (in shares) at Dec. 31, 2022	1,270	35,869
Balance at Dec. 31, 2022	$ 1	$ 36	232,546	(428,985)	(5,452)	(201,854)
Issuance of common stock (in shares)	0	4,499
Issuance of common stock	$ 0	$ 4	21,714	0	0	21,718
Series B conversion to common stock (in shares)	(1,270)	(127)
Series B conversion to common stock	$ (1)	$ 1	0	0	0	0
Series B conversion to common stock (in shares)	1,270	127
Stock options exercised (in shares)	0	183
Stock options exercised	$ 0	$ 0	133	0	0	133
Stock-based compensation	$ 0	$ 0	7,660	0	0	7,660
Issuance and exercise of warrants (in shares)	0	288
Issuance and exercise of warrants	$ 0	$ 0	2,005	0	0	2,005
Foreign currency translation loss	0	0	0	0	(219)	(219)
Net loss	$ 0	$ 0	0	(46,420)	0	(46,420)
Series B conversion to common stock (in shares)	1,270	127
Balance (in shares) at Dec. 31, 2023	0	40,966
Balance at Dec. 31, 2023	$ 0	$ 41	$ 264,058	$ (475,405)	$ (5,671)	$ (216,977)

Note 1 - Nature of Activities a

Note 1 - Nature of Activities and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Nature of Activities ● Aemetis Americas, Inc., a Delaware corporation, and its subsidiary AE Biofuels, Inc., a Delaware corporation; ● Aemetis International, Inc., a Nevada corporation, and its subsidiary International Biofuels Ltd, a Mauritius corporation, and its subsidiary Universal Biofuels Private Limited, an India company; ● Aemetis Technologies, Inc., a Delaware corporation; ● Aemetis Biofuels, Inc., a Delaware corporation, and its subsidiary Energy Enzymes, Inc., a Delaware corporation; ● AE Advanced Fuels, Inc., a Delaware corporation, and its subsidiaries Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, and Aemetis Property Keyes, Inc., a Delaware corporation; ● Aemetis Advanced Fuels, Inc., a Nevada corporation; ● Aemetis Advanced Products Keyes, Inc., a Delaware corporation, and its subsidiaries Aemetis Properties Riverbank, Inc., a Delaware corporation, Aemetis Health Products, Inc., a Delaware corporation; and Aemetis Riverbank, Inc., a Delaware corporation, and its subsidiary Aemetis Advanced Products Riverbank, Inc., a Delaware corporation; ● Aemetis Advanced Biorefinery Keyes, Inc., a Delaware corporation; ● Aemetis Carbon Capture, Inc. a Nevada corporation; ● Aemetis Biogas LLC, a Delaware Limited Liability Company and its subsidiaries Aemetis Biogas Services LLC, a Delaware Limited Liability Company, and Aemetis Biogas Holdings LLC, a Delaware Limited Liability Company, and its subsidiaries Aemetis Biogas 1 2 3 4 5 6 7 8 ● Goodland Advanced Fuels, Inc., a Nevada corporation. Founded in 2006 three not Basis of Presentation and Consolidation. not All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates Revenue Recognition 606 California Ethanol: 2022 second 2023, second 2023, not Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, May 25, 2023, one During the last two December 2022, first second 2023 May 2023. The following table shows our sales in California Ethanol by product category: California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 California Dairy Renewable Natural Gas: December 31, 2023, seven 26 2023, seven "D3 D3 third 2023 first 2024. D3 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel: not one The following table shows our sales in India by product category: India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111 Cost of Goods Sold January May 2023, Shipping and Handling Costs Research and Development. Cash, Cash Equivalents, and Restricted Cash three may not AB1 AB2 The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999 Accounts Receivable. The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third may 30 The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may Inventories first first Other current assets Variable Interest Entities. 1 2 not Property, Plant and Equipment. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360 10 35 Property Plant and Equipment Subsequent Measurement, may not may not not December 31, 2023 2022 Grants Received. California Energy Commission Low-Carbon Fuel Production Program December 31, 2023 California Department of Food and Agriculture Dairy Digester Research and Development Grant 2 019, two second 2021. October 2020, six 2020 December 31, 2023 California Energy Commission Low Carbon Advanced Ethanol Grant Program. May 2019, not not not December 31, 2023 2022 U.S. Department of Food and Agriculture Forest Service Grant. December 31, 2023 California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. 1.56 1.25MW/2.5MWh December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. 2 100% December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. December 31, 2023 U.S. Forest Service Community Wood Grant. May 2022. 3 no December 31, 2023 USDA Biofuel Producer Program Grant. second 2022, 19 California Energy Commission Grant for Mechanical Vapor Recompression System. December 31, 2023 PG&E A2313 February 2023, Pacific Gas and Electric SEM Manufacturer s Incentive Program. fourth 2022, Investment Tax Credits. third 2023, third 740 December 31, 2023. October 2023, Income Taxes 740 Income Taxes 740 not may not December 31, 2023 2022 The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may In 2018, 1 2 Basic and Diluted Net Income (Loss) per Share. December 31, 2023 2022 The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 2022 As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417 Comprehensive Loss. 220 Comprehensive Income not Foreign Currency Translation/Transactions. Fair Value of Financial Instruments. not 3 Share Based Compensation. ize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest. Commitments and Contingencies. 450 Contingencies 450 one Convertible Instruments. Debt Issuance Costs. Troubled Debt Restructuring Accounting. Debt Modification Accounting 540 50 Debt Modification and Extinguishments 10 10 Recently Adopted Accounting Pronouncements In November 2023, 2023 07, 280 2023 07, 280 January 1, 2024, January 1, 2025. 2023 07 In December 2023, 2023 09, 740 January 1, 2025, 2023 09 There were no

Note 2 - Inventories

Note 2 - Inventories	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	2. Inventories consist of the following: As of December 31, 2023 December 31, 2022 Raw materials $ 9,907 $ 2,971 Work-in-progress 1,682 127 Finished goods 6,702 1,560 Total inventories $ 18,291 $ 4,658 As of December 31, 2023 December 31, 2022 of $58 thousand and $0.1 million

Note 3 - Property, Plant and Eq

Note 3 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property, plant and equipment consist of the following: As of December 31, 2023 December 31, 2022 Land $ 7,345 $ 7,344 Plant and buildings 136,318 99,116 Furniture and fixtures 2,266 1,831 Machinery and equipment 14,982 15,209 Construction in progress 73,057 88,990 Property held for development 15,431 15,437 Finance lease right of use assets 2,889 3,045 Total gross property, plant & equipment 252,288 230,972 Less accumulated depreciation (57,180 ) (50,531 ) Total net property, plant & equipment $ 195,108 $ 180,441 Interest capitalized in property, plant, and equipme nt was $5.6 million and $11.1 million for the years ended December 31, 2023 2022 , respectively. Construction in progress includes costs for the biogas construction projects (dairy digesters and not Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5 The Company recorded depreciation expense of approximat ely $6.9 million and $5.5 million respectively, for the years ended December 31, 2023 2022 .

Note 4 - Debt

Note 4 - Debt	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Debt consists of the notes from the Company’s senior lender, Third Eye Capital, acting as Agent for the Purchasers (Third Eye Capital), other working capital lenders and subordinated lenders as follows: December 31, 2023 December 31, 2022 Third Eye Capital term notes $ 7,159 $ 7,141 Third Eye Capital revolving credit facility 20,922 60,602 Third Eye Capital revolving notes Series B 54,412 - Third Eye Capital revenue participation term notes 12,011 11,963 Third Eye Capital acquisition term notes 26,655 26,578 Third Eye Capital Fuels Revolving Line 32,511 27,410 Third Eye Capital Carbon Revolving Line 23,486 22,710 Construction Loan 41,024 19,820 Cilion shareholder seller notes payable 7,028 6,821 Subordinated notes 17,625 15,931 EB-5 promissory notes 42,211 41,404 Working capital loans 3,827 - Term loans on capital expenditures 5,850 5,860 Total debt 294,721 246,240 Less current portion of debt 37,028 49,219 Total long term debt $ 257,693 $ 197,021 Third Eye Capital Note Purchase Agreement On July 6, 2012, On March 8, 2022, No. 22 No. 22” December 31, 2021, ( December 31, 2021. On May 11, 2022, No. 23 No. 23” March 31, 2022, ( March 31, 2023 March 31, 2022 On August 8, 2022, No. 24 No. 24" may April 1, 2024 may No. 24 On March 6, 2023, No. 25 No. 25” March 31, 2023, not 10 On May 4, 2023, No. 26 No. 26” June 30, 2023, not No. 26 470 50 470 60 On May 16, 2023, No. 27 No. 27” may April 1, 2025 may No. 27 470 50 470 60 According to ASC 470 10 45 not 12 four 5 February 2024, one April 1, 2025. December 31, 2023. On March 25, 2024, No. 28 No. 28” 120%. No. 28, No. 28 470 50 On March 6, 2020, one March 14, 2021, August 9, 2021, March 25, 2024, April 1, 2025. April 1, 2025. may may April 1, 2025. Terms of Third Eye Capital Notes A. Term Notes December 31, 2023 April 1, 2025. B. Revolving Credit Facility December 31, 2023 April 1, 2025. December 31, 2023 C. Revolving Notes Series B. December 31, 2023) April 1, 2025. December 31, 2023, D. Revenue Participation Term Notes April 1, 2025. December 31, 2023 E. Acquisition Term Notes December 31, 2023 April 1, 2025. December 31, 2023 not F. Reserve Liquidity Notes . The Reserve Liquidity Notes, with available borrowing capacity in the amount of $85.0 million, accrues interest at the rate of 30% per annum and are due and payable upon the earlier of: (i) the closing of new debt or equity financings, (ii) receipt from any sale, merger, debt or equity financing, or (iii) April 1, 2025. December 31, 2023 . The Third Eye Capital Notes contain various covenants, including but not not twelve The Third Eye Capital Notes are secured by first Third Eye Capital Revolving Credit Facility for Fuels and Carbon Lines. March 2, 2022, two March 1, 2025 ten December 31, 2023 March 1, 2026 eight December 31, 2023 five March 2, 2022; ten March 2, 2022. As of December 31, 2023 GAFI had $33.9 million in principal and interest outstanding and $1.3 million unamortized debt issuance costs. As of December 31, 2023 , ACCI had $25.2 million in principal and interest outstanding and $1.7 million in unamortized debt issuance costs. Cilion shareholder seller notes payable July 6, 2012, December 31, 2023 Subordinated Notes. January 6 January 9, 2012, two six six two may On January 1, 2023, two June 30, 2023; ( two July 1, 2023, two December 31, 2023; ( two January 1, 2023 July 1 2023 470 50 On January 1, 2024, two June 30, 2024; ( two At December 31, 2023 2022 EB- 5 5 March 4, 2011 ( January 19, 2012 July 24, 2012) 5 72 5 2 3%. four 5 one two one no February 27, 2019, 5 six six 5 12 5 19 829 5 three Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB- 5 5 2012 December 31, 2023 December 31, 2023 5 5 On October 16, 2016, 5 5 5 5 November 21, 2019, 5 100 5 May 1, 2020 No. 3 5 60. 5 52 5 may five The Company has sold an aggregate principal amount of $4.0 million of EB- 5 5 2016 December 31, 2023 $4.0 December 31, 2023 5 5 Working capital loans. July 26, 2022, not August 1, 2022, not one December 31, 2023 2022, none, Secured loans . first 2023, November 15, 2023 May 3, 2024. December 31, 2023 December 31, 2022, no Aemetis Biogas 1 October 4, 2022, “AB1 AB1 1 AB1 December 22, 2023, AB1 "AB1 AB1 1 five five January 22, 2024, ( January 22, 2025, December 22, 2042, AB1 2025, AB1 December 31, 2023 December 31, 2022, none, AB1 Aemetis Biogas 2 July 28, 2023, second “AB2 AB2 not 2 five five AB2 August 15, 2023, ( August 15, 2025, July 28, 2043, AB2 2025, AB2 December 31, 2023 December 31, 2022, none, none, AB2 Financing Agreement for capital expenditures. TM We recorded the asset in property, plant and equipment, net and recorded the related liability of $2.0 million in short term borrowings and $3.8 million in other long-term debt, respectively as of December 31, 2023 Debt repayments for the Company’s loan obligations follow: Twelve months ended December 31, Debt Repayments 2024 $ 37,028 2025 181,464 2026 37,912 2027 4,128 2028 2,108 There after 37,545 Total debt 300,185 Debt issuance costs (5,464 ) Total debt, net of debt issuance costs $ 294,721

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5. Leases The Company is a party to operating leases for the Company's corporate office in Cupertino, modular offices, and laboratory facilities. We have also entered into several finance leases for mobile equipment and for the Riverbank Industrial Complex. These finance leases have a purchase option at the end of the term that we are reasonably certain we will exercise, so the leases are classified as finance leases. All of our leases have remaining term of one 12 The Company evaluates leases in accordance with ASC 842 The components of lease expense and sublease income is as follows: Twelve Months Ended December 31, 2023 2022 Operating lease cost Operating lease expense $ 722 $ 673 Short term lease expense 223 176 Variable lease expense 93 91 Total operating lease cost $ 1,038 $ 940 Finance lease cost Amortization of right-of-use assets $ 121 $ 179 Interest on lease liabilities 340 310 Total finance lease cost $ 461 $ 489 Cash paid for amounts included in the measurement of lease liabilities: Twelve Months Ended December 31, 2023 2022 Operating cash flows used in operating leases $ 668 $ 766 Operating cash flows used in finance leases 340 310 Financing cash flows used in finance leases 428 481 Supplemental non-cash flow information related to the operating ROU asset and lease liabilities for the year ended December 31, 2023 2022 Twelve Months Ended December 31, 2023 2022 Operating leases Accretion of the lease liability $ 249 $ 340 Amortization of right-of-use assets 293 333 Weighted Average Remaining Lease Term Operating leases (in years) 4.2 5.2 Finance leases (in years) 13.0 14.0 Weighted Average Discount Rate Operating leases 14.1 % 14.2 % Finance leases 13.2 % 13.2 % Supplemental balance sheet information related to leases was as follows: As of December 31, 2023 December 31, 2022 Operating leases Operating lease right-of-use assets $ 2,056 $ 2,449 Current portion of operating lease liability 406 338 Long term operating lease liability 1,783 2,189 Total operating lease liabilities 2,189 2,527 Finance leases Property and equipment, at cost $ 2,889 $ 3,045 Accumulated depreciation (228 ) (112 ) Property and equipment, net 2,661 2,933 Other current liability 30 71 Other long term liabilities 2,687 2,911 Total finance lease liabilities 2,717 2,982 Maturities of operating lease liabilities were as follows: Year Ended December 31, Operating leases Finance leases 2024 $ 682 $ 179 2025 681 168 2026 626 145 2027 645 145 2028 272 145 There after - 10,105 Total lease payments 2,906 10,887 Less imputed interest (717 ) (8,170 ) Total lease liability $ 2,189 $ 2,717 The Company acts as sublessor in certain leasing arrangements, primarily related to land and buildings. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on net basis on the consolidated financial statements. Sublease income is recorded in the other operating income section of the Consolidated Statements of Operations and Comprehensive Loss. The components of lease income for the years ended December 31, 2023 2022 were as follows: December 31, 2023 December 31, 2022 Lease income $ 2,075 $ 1,255 Future lease commitments to be received by the Company as of December 31, 2023 , are as fo Year ended December 31, 2024 $ 948 2025 773 2026 562 2027 508 2028 508 There after 635 Total future lease commitments $ 3,934 Legal Proceedings On August 31, 2016, July 24, 2019, May 6, 2022 second 2022. The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of these matters is not not

Note 6 - Aemetis Biogas - Serie

Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	6. Series A Preferred Financing and Variable Interest Entity On December 20, 2018, X ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company at $5.00 per common unit for a total of $30,000,000 in funding. Additionally, 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below. Prior to August 8, 2022, second 10 one one one three sixth not Prior to August 8, 2022, may one one December 31, 2023 not may 100% 75% From inception of the agreement to August 8, 2022, first second On August 8th, 2022, December 31, 2022, ( September 30, 2022, January 1, 2023. 470 50 On January 1, 2023, not December 31, 2022, May 31, 2023, June 1, 2023 May 31, 2024, 470 60 no December 31, 2022, seventeen May 31, 2024. On May 31, 2023, not May 31, 2023 August 31, 2023, September 1, 2023 August 31, 2024, 470 60 no May 31, 2023 fifteen August 31, 2024. On October 6, 2023, On November 8, 2023, not August 31, 2023 December 31, 2023, fourth January 1, 2024 December 31, 2024, fourth 470 60 no November 8, 2023 December 31, 2024. On February 8, 2024, not December 31, 2023 April 30, 2024, not May 1, 2024 April 30, 2025, fifth fifth 470. December 31, 2023. The Company recorded carrying value of Series A Preferred Unit liabilities as long-term liabilities of $113.2 million and $116.0 million as of December 31, 2023 2022 , respectively. Variable interest entity assessment After consideration of ABGL’s operations and the above agreement, we concluded that ABGL did not December 31, 2023

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	7. Equity Common Stock The Company is authorized to issue 80 million shares of common stock, $0.001 par value per share. Convertible Preferred Stock The company is authorized to issue up to 65 million shares of preferred stock, $0.001 par value per share. Effective as of December 12, 2023, one December 31, 2023, Shares Issued and Authorized Outstanding December 31, Shares 2023 2022 Series B preferred stock 7,235 - 1,270 Undesignated 57,765 - - 65,000 - 1,270

Note 8 - Warrants to Purchase C

Note 8 - Warrants to Purchase Common Stocks	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Outstanding Warrants [Text Block]	8. During 2023, ● A warrant issued to a vendor exercisable for the purchase of 100,000 shares at an exercise price of $2.50 per share with a two 2023 ● Warrants issued to the Company's senior lender exercisable for 160,000 shares of the Company's common stock at an exercise price of $2.00 per share with a five December 31, 2023. ● In connection with a credit line increase, a warrant issued to the Company's senior lender was automatically modified to increase the number of shares that may ● Warrants issued to subordinated lenders exercisable for 226,666 at an exercise price of $0.01 per share and a term of two 2023 The following table shows the weighted average fair value calculations for warrants granted based on the listed weighted average assumptions: Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.85 % 1.75 % Expected volatility 117.90 % 151.41 % Expected life (years) 5 3 Exercise price per share $ 1.62 $ 10.47 Market value per share on grant date $ 4.13 $ 11.29 Fair value per share on grant date $ 3.92 $ 9.68 A summary of historical warrant activity for the years ended December 31, 2023 2022 Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2021 55 $ 2.59 4.95 Granted 527 10.47 Exercised (227 ) 0.01 Outstanding December 31, 2022 355 $ 15.92 7.48 Granted 511 1.62 Exercised (336 ) 0.83 Outstanding December 31, 2023 530 $ 11.70 5.77 All of the above outstanding warrants are vested and exercisable as of December 31, 2023 .

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. 2019 On August 26, 2021, 2019 “2019 2019 April 25, 2019, 2019 2019 July 1, 2021, 2019 January 1 January 1 Pursuant to the 2019 December 31, 2023 2022, December 31, 2023 2022, The following table summarizes activity under the 2019 2022 2023: Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 42 3,763 $ 2.29 Authorized 1,338 - - Options Granted (1,307 ) 1,307 10.97 RSAs Granted (89 ) - - Exercised - (295 ) 0.93 Forfeited/expired 81 (81 ) 11.63 Balance as of December 31, 2022 65 4,694 $ 4.63 Authorized 1,644 - - Options Granted (1,278 ) 1,278 3.60 RSAs Granted (244 ) - - Exercised - (177 ) 1.83 Forfeited/expired 269 (269 ) 5.93 Balance as of December 31, 2023 456 5,526 $ 4.42 The following table summarizes vested and unvested option awards outstanding as of December 31, 2023 2022 Number of Shares Weighted Average Exercise Price Remaining Contractual Term (In Years) Aggregate Intrinsic Value1 2023 Vested and Exercisable 3,986 $ 3.58 6.47 $ 11,695 Unvested 1,540 6.55 8.67 1,621 Total 5,526 $ 4.42 7.04 $ 13,316 2022 Vested and Exercisable 3,170 $ 2.46 6.98 $ 7,419 Unvested 1,524 9.13 8.81 647 Total 4,694 $ 4.63 7.58 $ 8,066 ( 1 Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 2022 respectively, as reported on the NASDAQ Exchange. Inducement Equity Plan Options In March 2016, December 31, 2023 not Stock-based Compensation Expense Stock-based compensation is accounted for in accordance with ASC 718, Compensation - Stock Compensation n estimated fair value on the grant date. We estimate the fair value using the Black-Scholes option pricing model and recognize that fair value as an expense over the vesting period of each grant using the straight-line method. W No. 107, Share-Based Payment not zero The weighted average fair value for options granted during the years ended 2023 2022 Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.86 % 2.03 % Expected volatility 124.62 % 117.21 % Expected life (years) 7.00 7.00 Market value per share on grant date $ 3.60 $ 10.97 Fair value per share on grant date $ 3.29 $ 9.71 For the years ended December 31, 2023 2022 $7.7 million, and $6.4 million, respectively. December 31, 2023

Note 10 - Agreements

Note 10 - Agreements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	10. Working Capital Arrangement. May 2023, As of December 31, 2023 2022 , Aemetis made prepayments to J.D. Heiskell of none December 31, 2023 2022 As of and for the twelve months ended December 31, 2023 2022 Ethanol sales $ 77,359 $ - Wet distiller's grains sales 21,963 50,930 CDO and CDS sales 3,296 10,168 Corn purchases 83,128 191,401 Accounts receivable 1,073 - Accounts payable 1,207 27 Ethanol and Wet Distillers Grains Marketing Arrangement. The Company entered into a Fuel Ethanol Purchase and Sale Agreement with Murex, which matures on October 31, 2023, one May 30, 2023 No. 1 October 1, 2023 March 31, 2025. December 31, 2024, one For the years ended December 31, 2023 2022 sts of $1.5 million and $2.9 million, respectively, For the years ended December 31, 2023 2022 ol $1.7 million and $3.3 million for each period and expensed transportation costs related to sales of WDG of $3.3 million and $5.3 million. Supply Trade Agreement. July 1, 2022, ten one one December 31, 2023 2022 As of December 31, 2023

Note 11 - Segment Information

Note 11 - Segment Information	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	11. Aemetis recognizes three The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year ethanol plant in Keyes, California, and the adjacent land leased for the production of CO₂. The “California Dairy Renewable Natural Gas” reportable segment including the production and sale of Renewable Natural Gas and associated environmental attributes, consisting of anaerobic digesters located at diaries, at 36 The “India Biodiesel” reportable segment includes the Company’s 60 million gallon per year nameplate capacity biodiesel manufacturing plant in Kakinada India, and administrative offices in Hyderabad, India. The Company has additional operating segments that were determined not Summarized financial information by reportable segment for the years ended December 31, 2023 2022 For the year ended December 31, 2023 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 104,068 $ 5,455 $ 77,194 $ - $ 186,717 Intersegment revenues - - - - - Gross profit (loss) (6,602 ) (331 ) 8,950 - 2,017 Interest expense, including amortization of debt fees 25,258 2,809 447 11,005 39,519 Accretion and other expenses of Series A preferred units - 25,313 - - 25,313 Loss on Income tax expense (benefit) - (55,159 ) 1,416 7 (53,736 ) Capital expenditures 5,695 24,744 1,281 1,399 33,119 Depreciation 3,995 2,116 576 246 6,933 Total Assets 67,991 92,794 34,769 47,852 243,406 For the year ended December 31, 2022 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 228,194 $ 208 $ 28,111 $ - $ 256,513 Intersegment revenues - 1,002 - - 1,002 Gross profit (loss) (13,017 ) (778 ) 8,273 (13 ) (5,535 ) Interest expense, including amortization of debt fees 20,637 742 119 7,272 28,770 Accretion and other expenses of Series A preferred units - 9,888 - - 9,888 Income tax expense - 6 1,040 7 1,053 Loss on debt extinguishment - 49,386 - - 49,386 Capital expenditures 8,399 22,884 129 7,745 39,157 Depreciation 4,148 615 650 122 5,535 Total Assets 66,794 77,714 16,120 46,486 207,114 A reconciliation of reportable segment revenues to consolidated totals for the years 2023 2022 Revenues 2023 2022 Total revenues for reportable segments $ 186,717 $ 257,515 Elimination of intersegment revenues - (1,002 ) Total consolidated revenues $ 186,717 $ 256,513 California Ethanol: December 31, 2023 2022 one December 31, 2023 December 31, 2022 December 31, 2022 California Dairy Renewable Natural Gas: twelve December 31, 2023 one third 2023, D3 2023 twelve December 31, 2022, India Biodiesel: December 31, 2023 three December 31, 2022 three

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. The Company owes Eric McAfee, the Company’s Chairman and CEO, and McAfee Capital LLC (“McAfee Capital”), owned by Eric McAfee and his wife, $0.4 millio n in connection with employment agreements and expense reimbursements. T December 31, 2023. February 28, 2023, one December 31, 2023, The Company owes various members of its Board of Directors amounts totaling $0.3 million as of December 31, 2023 December 31, 2022 December 31, 2023 2022

Note 13 - Income Tax

Note 13 - Income Tax	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. The Company files a consolidated federal income tax return including all its domestic subsidiaries except for Aemetis Biogas LLC, which files its own returns. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries. Components of tax expense consist of the following: 2023 2022 Current: Federal $ (55,164 ) $ - State and Local 13 13 Foreign 1,489 230 (53,662 ) 243 Deferred: Federal - - State and Local - - Foreign (74 ) 810 Income tax (benefit) expense $ (53,736 ) $ 1,053 The Company records deferred tax liability in other long term liabilities in the Consolidated Balance Sheets. The deferred tax liability resulted as India subsidiary had income for the year ended December 31, 2023 Year Ended December 31, 2023 2022 United States $ (107,191 ) $ (112,959 ) Foreign 7,035 6,254 Pretax loss $ (100,156 ) $ (106,705 ) Income tax benefit differs from the amounts computed by applying the statutory U.S. federal income tax rate ( 21% Year Ended December 31, 2023 2022 Income tax benefit at the federal statutory rate $ (21,033 ) $ (22,408 ) State tax benefit (999 ) (496 ) Sale of tax credits (55,164 ) - Foreign tax differential 11 168 Stock-based compensation 2,048 295 Interest Expense 92 58 GILTI Inclusion - 1,126 Prior year true-ups (18,031 ) 55 Non-includible US Entities - 13,499 Other 67 46 Credits (869 ) (2,373 ) Valuation Allowance 40,142 11,083 Income Tax Expense (Benefit) (53,736 ) 1,053 Effective Tax Rate 53.65 % (0.99 )% The components of the net deferred tax asset or (liability) are as follows: Year Ended December 31, 2023 2022 Deferred Tax Assets Organizational Costs, Start-up and Intangible Assets $ 34,217 $ 2,309 Stock Based Compensation 1,239 1,842 NOLs, Unabsorbed Depreciation and R&D Credits C/F's 67,621 68,201 Interest expense carryover 29,066 22,374 Ethanol Credits 1,500 1,500 Carbon Oxide Sequestration Credit 6,696 5,827 Accrued Expenses 2,249 2,001 Operating Lease Liability 1,282 1,512 Other, net 248 113 Total Deferred Tax Assets 144,118 105,679 Valuation Allowance (135,354 ) (95,214 ) Net Deferred Tax Assets 8,764 10,465 Deferred Tax Liabilities Right of Use Asset (1,230 ) (1,477 ) Property, Plant & Equipment (8,266 ) (9,788 ) Other, net (3 ) (10 ) Total Deferred Tax Liabilities (9,499 ) (11,275 ) Net Deferred Tax Liabilities $ (735 ) $ (810 ) Based on the Company’s evaluation of current and anticipated future taxable income, the Company believes it is more likely than not We do not December 31, 2023 2022 December 31, 2022. may not ASC 740 not not not 12 December 31, 2023 not The following describes the open tax years, by major tax jurisdiction, as of December 31, 2023 United States — Federal 2007 – present United States — State 2008 – present India 2013 – present Mauritius 2006 – present As of December 31, 2023 2027 2043. 2027 2042. may December 31, 2023 no

Note 14 - Parent Company Financ

Note 14 - Parent Company Financial Statements (Unaudited)	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Condensed Financial Information of Parent Company Only Disclosure [Text Block]	14. We conduct substantially all of our operations through subsidiaries and are dependent on cash distributions, dividends and other intercompany transfers of funds from our operations. Our subsidiaries have not may not Aemetis, Inc. (Parent Company) Balance Sheets As of December 31, 2023 2022 2023 2022 Assets Current assets Cash and cash equivalents $ 1,454 $ 286 Receivables due from subsidiaries 110,083 98,780 Prepaid expenses 437 611 Other current assets 12 7 Total current assets 111,986 99,684 Investment in Aemetis Property Keyes, Inc. 1,556 1,274 Investment in Aemetis International, Inc. 12,059 6,659 Investment in Aemetis Advanced Products Riverbank, Inc. 638 173 Investment in AE Advanced Products Keyes , Inc. 246 - Total investments in Subsidiaries, net of advances 14,499 8,106 Property, plant and equipment, net 149 135 Other assets 2,096 2,377 Total Assets $ 128,730 $ 110,302 Liabilities & stockholders' deficit Current liabilities Accounts payable $ 3,633 $ 2,934 Mandatorily redeemable Series B convertible preferred 4,521 4,082 Other current liabilities 5,031 4,269 Total current liabilities 13,185 11,285 Long term liabilities: Operating lease liability 1,716 2,047 Subsidiary obligation in excess of investment Investment in AE Advanced Fuels, Inc. 220,571 177,856 Investment in Aemetis Americas, Inc 202 205 Investment in Aemetis Biofuels, Inc. 2,721 2,738 Investment in Aemetis Technologies, Inc. 4,868 4,716 Investment in AE Advanced Products Keyes , Inc. - 270 Investment in Aemetis Health Products, Inc. 2,084 2,076 Investment in Goodland Advanced Fuels, Inc. 22,982 16,869 Investment in Aemetis Biogas LLC 70,471 91,292 Investment in Aemetis Carbon Capture Inc 5,895 2,323 Investment in Aemetis Properties Riverbank, Inc. 1,012 479 Total subsidiary obligation in excess of investment 330,806 298,824 Total long term liabilities 332,522 300,871 Stockholders' deficit Series B Preferred convertible stock - 1 Common stock 41 36 Additional paid-in capital 264,058 232,546 Accumulated deficit (475,405 ) (428,985 ) Accumulated other comprehensive loss (5,671 ) (5,452 ) Total stockholders' deficit (216,977 ) (201,854 ) Total liabilities & stockholders' deficit $ 128,730 $ 110,302 Aemetis, Inc. (Parent Company) Statements of Operations and Comprehensive Loss For the Years Ended December 31, 2023 2022 2023 2022 Equity in subsidiary losses $ (25,370 ) $ (91,561 ) Selling, general and administrative expenses 19,218 15,203 Operating loss (44,588 ) (106,764 ) Other (income) expense Interest expense 1,073 806 Debt related fees and amortization expense 781 1,581 Other income (30 ) (1,400 ) Loss before income taxes (46,412 ) (107,751 ) Income tax expense 8 7 Net loss (46,420 ) (107,758 ) Other comprehensive loss Foreign currency translation adjustment (219 ) (1,102 ) Comprehensive loss $ (46,639 ) $ (108,860 ) Aemetis, Inc. (Parent Company) Statements of Cash Flows For the years ended December 31, 2023 2022 2023 2022 Operating activities: Net loss (46,420 ) (107,758 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 7,660 6,410 Depreciation 51 29 Debt related fees and amortization expense 782 1,776 Subsidiary portion of net losses 25,370 91,561 Gain on litigation - (1,400 ) Warrants issued for working capital agreement 409 - Changes in assets and liabilities: Prepaid expenses (608 ) 111 Accounts payable 699 (90 ) Accrued interest expense 785 778 Other liabilities 85 (4,625 ) Other assets 276 207 Net cash used in operating activities (10,911 ) (13,001 ) Investing activities: Capital expenditures (65 ) (128 ) Subsidiary advances, net (9,707 ) 1,222 Net cash provided by (used in) investing activities (9,772 ) 1,094 Financing activities: Proceeds from the exercise of stock options 133 206 Proceeds from issuance of common stock in equity offering 21,718 11,987 Net cash provided by financing activities 21,851 12,193 Net increase in cash, cash equivalents, and restricted cash 1,168 286 Cash, cash equivalents and restricted cash at beginning of period 286 - Cash, cash equivalents, and restricted cash at end of period $ 1,454 $ 286 Supplemental disclosures of cash flow information, cash paid: Income taxes paid 7 7 Supplemental disclosures of cash flow information, non-cash transactions: Fair value of warrants issued to subordinated debt holders 1,278 1,939 Fair value of stock issued to a related party for guarantee fees - 2,012 Fair value of warrants issued for capital expenditures 318 - Fair value of warrants issued to lender for debt issuance costs - 3,158 Fair value of stock issued to lender - 1,335

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subordinated Notes On January 1, 2024, two June 30, 2024; ( not two Series A Preferred Unit Purchase Agreement On February 8, 2024, April 30, 2024, twelve not Third Eye Capital Reserve Liquidity Facility On March 25, 2024, $85 April 1, 2025. April 1, 2025. 30% 40% may 2% may April 1, 2025. Third Eye Capital Limited Waiver and Amendment No. 28 On March 25, 2024, No. 28 No. 28” 120%. No. 28,

Note 16 - Liquidity

Note 16 - Liquidity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	16. Liquidity The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. As a result of negative capital, negative operating results, and collateralization of substantially all of the Company assets, the Company has been reliant on its senior secured lender to provide additional funding and has been required to remit substantially all excess cash from operations to the senior secured lender. In order to meet our obligations during the next twelve April 1, 2025, twelve December 31, 2023. Operations and Project Development For the Keyes Plant, we plan to operate the plant and continue to improve its financial performance by adopting new technologies or process changes that allow for energy efficiency, cost reduction, or revenue enhancements, as well as, execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon emissions, and overall margin improvement. For Aemetis Biogas, we plan to operate our existing biogas digesters to produce and sell Renewable Natural Gas (RNG) and the associated Federal D3 2023 2024, For the Kakinada Plant, we plan to continue to sell our biodiesel to OMCs pursuant to cost-plus contracts. We are also continuing to upgrade the plant to increase feedstock flexibility (and thereby lower feedstock costs), increase production capacity, and produce new products. Additionally, we are in the process of obtaining approval and contractual arrangements for the export of refined animal tallow into international markets. Financing We plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, entering into additional debt agreements for specific projects, obtaining project specific equity and debt for development projects, and obtaining additional debt from the current EB- 5

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023 shares
ecd_TradingArrByIndTable
Material Terms of Trading Arrangement [Text Block]	9B. Other Information. (a) Current Reports On March 25, 2024, two No. 28 4, 15, 8 two 10.36 10.37, two 8 10.36 10.37. (b) Adoption and Termination 10b5 1 On September 15, 2023 Francis P. Barton Board of Directors adopted 10b5 1 December 15, 2023, ( December 31, 2024, ( may 10b5 1 On September 15, 2023 Todd A. Waltz Executive Vice President and Chief Financial Officer adopted 10b5 1 January 1, 2024, ( June 15, 2025, ( may 10b5 1 December 31, 2023, 475,000 No On November 13, 2023 Andrew B. Foster Executive Vice President and Chief Operating Officer adopted 10b5 1 February 14, 2024, ( December 31, 2024, ( may 10b5 1 10b5 1 December 31, 2023, 96,000 No
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
AMTX_Francis P. Barton [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Securities Aggregate Available Amount	126,000
Trading Arrangement Adoption Date	September 15, 2023
Trading Arrangement, Individual Name	Francis P. Barton
Trading Arrangement, Individual Title	Board of Directors Member
Rule 10b5-1 Arrangement Adopted [Flag]	true
AMTX, Todd A. Waltz [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Securities Aggregate Available Amount	475,000
Trading Arrangement Adoption Date	September 15, 2023
Trading Arrangement, Individual Name	Todd A. Waltz
Trading Arrangement, Individual Title	Executive Vice President and Chief Financial Officer
Rule 10b5-1 Arrangement Adopted [Flag]	true
AMTX_Andrew B. Foster [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Securities Aggregate Available Amount	199,616
Trading Arrangement Adoption Date	November 13, 2023
Trading Arrangement, Individual Name	Andrew B. Foster
Trading Arrangement, Individual Title	Executive Vice President and Chief Operating Officer
Rule 10b5-1 Arrangement Adopted [Flag]	true

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Consolidation. not All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Revenue [Policy Text Block]	Revenue Recognition 606 California Ethanol: 2022 second 2023, second 2023, not Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, May 25, 2023, one During the last two December 2022, first second 2023 May 2023. The following table shows our sales in California Ethanol by product category: California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 California Dairy Renewable Natural Gas: December 31, 2023, seven 26 2023, seven "D3 D3 third 2023 first 2024. D3 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel: not one The following table shows our sales in India by product category: India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111
Cost of Goods and Service [Policy Text Block]	Cost of Goods Sold January May 2023,
Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs
Research and Development Expense, Policy [Policy Text Block]	Research and Development.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash three may not AB1 AB2 The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999
Receivable [Policy Text Block]	Accounts Receivable. The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third may 30 The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may
Inventory, Policy [Policy Text Block]	Inventories first first
Other Current Assets Policy [Policy Text Block]	Other current assets
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities. 1 2 not
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360 10 35 Property Plant and Equipment Subsequent Measurement, may not may not not December 31, 2023 2022
Government Assistance [Policy Text Block]	Grants Received. California Energy Commission Low-Carbon Fuel Production Program December 31, 2023 California Department of Food and Agriculture Dairy Digester Research and Development Grant 2 019, two second 2021. October 2020, six 2020 December 31, 2023 California Energy Commission Low Carbon Advanced Ethanol Grant Program. May 2019, not not not December 31, 2023 2022 U.S. Department of Food and Agriculture Forest Service Grant. December 31, 2023 California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. 1.56 1.25MW/2.5MWh December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. 2 100% December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. December 31, 2023 U.S. Forest Service Community Wood Grant. May 2022. 3 no December 31, 2023 USDA Biofuel Producer Program Grant. second 2022, 19 California Energy Commission Grant for Mechanical Vapor Recompression System. December 31, 2023 PG&E A2313 February 2023, Pacific Gas and Electric SEM Manufacturer s Incentive Program. fourth 2022,
Regulatory Income Taxes, Policy [Policy Text Block]	Investment Tax Credits. third 2023, third 740 December 31, 2023. October 2023,
Income Tax, Policy [Policy Text Block]	Income Taxes 740 Income Taxes 740 not may not December 31, 2023 2022 The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may In 2018, 1 2
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income (Loss) per Share. December 31, 2023 2022 The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 2022 As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss. 220 Comprehensive Income not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation/Transactions.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments. not 3
Share-Based Payment Arrangement [Policy Text Block]	Share Based Compensation. ize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest.
Commitments and Contingencies, Policy [Policy Text Block]	Commitments and Contingencies. 450 Contingencies 450 one
Debt, Policy [Policy Text Block]	Convertible Instruments. Debt Issuance Costs. Troubled Debt Restructuring Accounting. Debt Modification Accounting 540 50 Debt Modification and Extinguishments 10 10
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In November 2023, 2023 07, 280 2023 07, 280 January 1, 2024, January 1, 2025. 2023 07 In December 2023, 2023 09, 740 January 1, 2025, 2023 09 There were no

Note 1 - Nature of Activities_2

Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111
Schedule of Cash and Cash Equivalents [Table Text Block]	As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of December 31, 2023 December 31, 2022 Raw materials $ 9,907 $ 2,971 Work-in-progress 1,682 127 Finished goods 6,702 1,560 Total inventories $ 18,291 $ 4,658

Note 3 - Property, Plant and _2

Note 3 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of December 31, 2023 December 31, 2022 Land $ 7,345 $ 7,344 Plant and buildings 136,318 99,116 Furniture and fixtures 2,266 1,831 Machinery and equipment 14,982 15,209 Construction in progress 73,057 88,990 Property held for development 15,431 15,437 Finance lease right of use assets 2,889 3,045 Total gross property, plant & equipment 252,288 230,972 Less accumulated depreciation (57,180 ) (50,531 ) Total net property, plant & equipment $ 195,108 $ 180,441
Depreciation Of Property, Plant, and Equipment [Table Text Block]	Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5

Note 4 - Debt (Tables)

Note 4 - Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2023 December 31, 2022 Third Eye Capital term notes $ 7,159 $ 7,141 Third Eye Capital revolving credit facility 20,922 60,602 Third Eye Capital revolving notes Series B 54,412 - Third Eye Capital revenue participation term notes 12,011 11,963 Third Eye Capital acquisition term notes 26,655 26,578 Third Eye Capital Fuels Revolving Line 32,511 27,410 Third Eye Capital Carbon Revolving Line 23,486 22,710 Construction Loan 41,024 19,820 Cilion shareholder seller notes payable 7,028 6,821 Subordinated notes 17,625 15,931 EB-5 promissory notes 42,211 41,404 Working capital loans 3,827 - Term loans on capital expenditures 5,850 5,860 Total debt 294,721 246,240 Less current portion of debt 37,028 49,219 Total long term debt $ 257,693 $ 197,021
Schedule of Maturities of Long-Term Debt [Table Text Block]	Twelve months ended December 31, Debt Repayments 2024 $ 37,028 2025 181,464 2026 37,912 2027 4,128 2028 2,108 There after 37,545 Total debt 300,185 Debt issuance costs (5,464 ) Total debt, net of debt issuance costs $ 294,721

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	Twelve Months Ended December 31, 2023 2022 Operating lease cost Operating lease expense $ 722 $ 673 Short term lease expense 223 176 Variable lease expense 93 91 Total operating lease cost $ 1,038 $ 940 Finance lease cost Amortization of right-of-use assets $ 121 $ 179 Interest on lease liabilities 340 310 Total finance lease cost $ 461 $ 489 Twelve Months Ended December 31, 2023 2022 Operating cash flows used in operating leases $ 668 $ 766 Operating cash flows used in finance leases 340 310 Financing cash flows used in finance leases 428 481
Supplemental Non-cash Flow Information Related to Leases [Table Text Block]	Twelve Months Ended December 31, 2023 2022 Operating leases Accretion of the lease liability $ 249 $ 340 Amortization of right-of-use assets 293 333 Weighted Average Remaining Lease Term Operating leases (in years) 4.2 5.2 Finance leases (in years) 13.0 14.0 Weighted Average Discount Rate Operating leases 14.1 % 14.2 % Finance leases 13.2 % 13.2 %
Supplemental Balance Sheet Information Related to Leases [Table Text Block]	As of December 31, 2023 December 31, 2022 Operating leases Operating lease right-of-use assets $ 2,056 $ 2,449 Current portion of operating lease liability 406 338 Long term operating lease liability 1,783 2,189 Total operating lease liabilities 2,189 2,527 Finance leases Property and equipment, at cost $ 2,889 $ 3,045 Accumulated depreciation (228 ) (112 ) Property and equipment, net 2,661 2,933 Other current liability 30 71 Other long term liabilities 2,687 2,911 Total finance lease liabilities 2,717 2,982
Lease Term [Table Text Block]	Year Ended December 31, Operating leases Finance leases 2024 $ 682 $ 179 2025 681 168 2026 626 145 2027 645 145 2028 272 145 There after - 10,105 Total lease payments 2,906 10,887 Less imputed interest (717 ) (8,170 ) Total lease liability $ 2,189 $ 2,717
Operating Lease, Lease Income [Table Text Block]	December 31, 2023 December 31, 2022 Lease income $ 2,075 $ 1,255
Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]	Year ended December 31, 2024 $ 948 2025 773 2026 562 2027 508 2028 508 There after 635 Total future lease commitments $ 3,934

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stock by Class [Table Text Block]	Shares Issued and Authorized Outstanding December 31, Shares 2023 2022 Series B preferred stock 7,235 - 1,270 Undesignated 57,765 - - 65,000 - 1,270

Note 8 - Warrants to Purchase_2

Note 8 - Warrants to Purchase Common Stocks (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Warrants, Valuation Assumptions [Table Text Block]	Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.85 % 1.75 % Expected volatility 117.90 % 151.41 % Expected life (years) 5 3 Exercise price per share $ 1.62 $ 10.47 Market value per share on grant date $ 4.13 $ 11.29 Fair value per share on grant date $ 3.92 $ 9.68
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2021 55 $ 2.59 4.95 Granted 527 10.47 Exercised (227 ) 0.01 Outstanding December 31, 2022 355 $ 15.92 7.48 Granted 511 1.62 Exercised (336 ) 0.83 Outstanding December 31, 2023 530 $ 11.70 5.77

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 42 3,763 $ 2.29 Authorized 1,338 - - Options Granted (1,307 ) 1,307 10.97 RSAs Granted (89 ) - - Exercised - (295 ) 0.93 Forfeited/expired 81 (81 ) 11.63 Balance as of December 31, 2022 65 4,694 $ 4.63 Authorized 1,644 - - Options Granted (1,278 ) 1,278 3.60 RSAs Granted (244 ) - - Exercised - (177 ) 1.83 Forfeited/expired 269 (269 ) 5.93 Balance as of December 31, 2023 456 5,526 $ 4.42
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	Number of Shares Weighted Average Exercise Price Remaining Contractual Term (In Years) Aggregate Intrinsic Value1 2023 Vested and Exercisable 3,986 $ 3.58 6.47 $ 11,695 Unvested 1,540 6.55 8.67 1,621 Total 5,526 $ 4.42 7.04 $ 13,316 2022 Vested and Exercisable 3,170 $ 2.46 6.98 $ 7,419 Unvested 1,524 9.13 8.81 647 Total 4,694 $ 4.63 7.58 $ 8,066
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.86 % 2.03 % Expected volatility 124.62 % 117.21 % Expected life (years) 7.00 7.00 Market value per share on grant date $ 3.60 $ 10.97 Fair value per share on grant date $ 3.29 $ 9.71

Note 10 - Agreements (Tables)

Note 10 - Agreements (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]	As of and for the twelve months ended December 31, 2023 2022 Ethanol sales $ 77,359 $ - Wet distiller's grains sales 21,963 50,930 CDO and CDS sales 3,296 10,168 Corn purchases 83,128 191,401 Accounts receivable 1,073 - Accounts payable 1,207 27

Note 11 - Segment Information (

Note 11 - Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	For the year ended December 31, 2023 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 104,068 $ 5,455 $ 77,194 $ - $ 186,717 Intersegment revenues - - - - - Gross profit (loss) (6,602 ) (331 ) 8,950 - 2,017 Interest expense, including amortization of debt fees 25,258 2,809 447 11,005 39,519 Accretion and other expenses of Series A preferred units - 25,313 - - 25,313 Loss on Income tax expense (benefit) - (55,159 ) 1,416 7 (53,736 ) Capital expenditures 5,695 24,744 1,281 1,399 33,119 Depreciation 3,995 2,116 576 246 6,933 Total Assets 67,991 92,794 34,769 47,852 243,406 For the year ended December 31, 2022 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 228,194 $ 208 $ 28,111 $ - $ 256,513 Intersegment revenues - 1,002 - - 1,002 Gross profit (loss) (13,017 ) (778 ) 8,273 (13 ) (5,535 ) Interest expense, including amortization of debt fees 20,637 742 119 7,272 28,770 Accretion and other expenses of Series A preferred units - 9,888 - - 9,888 Income tax expense - 6 1,040 7 1,053 Loss on debt extinguishment - 49,386 - - 49,386 Capital expenditures 8,399 22,884 129 7,745 39,157 Depreciation 4,148 615 650 122 5,535 Total Assets 66,794 77,714 16,120 46,486 207,114
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Revenues 2023 2022 Total revenues for reportable segments $ 186,717 $ 257,515 Elimination of intersegment revenues - (1,002 ) Total consolidated revenues $ 186,717 $ 256,513

Note 13 - Income Tax (Tables)

Note 13 - Income Tax (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2023 2022 Current: Federal $ (55,164 ) $ - State and Local 13 13 Foreign 1,489 230 (53,662 ) 243 Deferred: Federal - - State and Local - - Foreign (74 ) 810 Income tax (benefit) expense $ (53,736 ) $ 1,053
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, 2023 2022 United States $ (107,191 ) $ (112,959 ) Foreign 7,035 6,254 Pretax loss $ (100,156 ) $ (106,705 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2023 2022 Income tax benefit at the federal statutory rate $ (21,033 ) $ (22,408 ) State tax benefit (999 ) (496 ) Sale of tax credits (55,164 ) - Foreign tax differential 11 168 Stock-based compensation 2,048 295 Interest Expense 92 58 GILTI Inclusion - 1,126 Prior year true-ups (18,031 ) 55 Non-includible US Entities - 13,499 Other 67 46 Credits (869 ) (2,373 ) Valuation Allowance 40,142 11,083 Income Tax Expense (Benefit) (53,736 ) 1,053 Effective Tax Rate 53.65 % (0.99 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2023 2022 Deferred Tax Assets Organizational Costs, Start-up and Intangible Assets $ 34,217 $ 2,309 Stock Based Compensation 1,239 1,842 NOLs, Unabsorbed Depreciation and R&D Credits C/F's 67,621 68,201 Interest expense carryover 29,066 22,374 Ethanol Credits 1,500 1,500 Carbon Oxide Sequestration Credit 6,696 5,827 Accrued Expenses 2,249 2,001 Operating Lease Liability 1,282 1,512 Other, net 248 113 Total Deferred Tax Assets 144,118 105,679 Valuation Allowance (135,354 ) (95,214 ) Net Deferred Tax Assets 8,764 10,465 Deferred Tax Liabilities Right of Use Asset (1,230 ) (1,477 ) Property, Plant & Equipment (8,266 ) (9,788 ) Other, net (3 ) (10 ) Total Deferred Tax Liabilities (9,499 ) (11,275 ) Net Deferred Tax Liabilities $ (735 ) $ (810 )
Summary of Income Tax Examinations [Table Text Block]	United States — Federal 2007 – present United States — State 2008 – present India 2013 – present Mauritius 2006 – present

Note 14 - Parent Company Fina_2

Note 14 - Parent Company Financial Statements (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Condensed Balance Sheet [Table Text Block]	2023 2022 Assets Current assets Cash and cash equivalents $ 1,454 $ 286 Receivables due from subsidiaries 110,083 98,780 Prepaid expenses 437 611 Other current assets 12 7 Total current assets 111,986 99,684 Investment in Aemetis Property Keyes, Inc. 1,556 1,274 Investment in Aemetis International, Inc. 12,059 6,659 Investment in Aemetis Advanced Products Riverbank, Inc. 638 173 Investment in AE Advanced Products Keyes , Inc. 246 - Total investments in Subsidiaries, net of advances 14,499 8,106 Property, plant and equipment, net 149 135 Other assets 2,096 2,377 Total Assets $ 128,730 $ 110,302 Liabilities & stockholders' deficit Current liabilities Accounts payable $ 3,633 $ 2,934 Mandatorily redeemable Series B convertible preferred 4,521 4,082 Other current liabilities 5,031 4,269 Total current liabilities 13,185 11,285 Long term liabilities: Operating lease liability 1,716 2,047 Subsidiary obligation in excess of investment Investment in AE Advanced Fuels, Inc. 220,571 177,856 Investment in Aemetis Americas, Inc 202 205 Investment in Aemetis Biofuels, Inc. 2,721 2,738 Investment in Aemetis Technologies, Inc. 4,868 4,716 Investment in AE Advanced Products Keyes , Inc. - 270 Investment in Aemetis Health Products, Inc. 2,084 2,076 Investment in Goodland Advanced Fuels, Inc. 22,982 16,869 Investment in Aemetis Biogas LLC 70,471 91,292 Investment in Aemetis Carbon Capture Inc 5,895 2,323 Investment in Aemetis Properties Riverbank, Inc. 1,012 479 Total subsidiary obligation in excess of investment 330,806 298,824 Total long term liabilities 332,522 300,871 Stockholders' deficit Series B Preferred convertible stock - 1 Common stock 41 36 Additional paid-in capital 264,058 232,546 Accumulated deficit (475,405 ) (428,985 ) Accumulated other comprehensive loss (5,671 ) (5,452 ) Total stockholders' deficit (216,977 ) (201,854 ) Total liabilities & stockholders' deficit $ 128,730 $ 110,302
Condensed Income Statement [Table Text Block]	2023 2022 Equity in subsidiary losses $ (25,370 ) $ (91,561 ) Selling, general and administrative expenses 19,218 15,203 Operating loss (44,588 ) (106,764 ) Other (income) expense Interest expense 1,073 806 Debt related fees and amortization expense 781 1,581 Other income (30 ) (1,400 ) Loss before income taxes (46,412 ) (107,751 ) Income tax expense 8 7 Net loss (46,420 ) (107,758 ) Other comprehensive loss Foreign currency translation adjustment (219 ) (1,102 ) Comprehensive loss $ (46,639 ) $ (108,860 )
Condensed Cash Flow Statement [Table Text Block]	2023 2022 Operating activities: Net loss (46,420 ) (107,758 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 7,660 6,410 Depreciation 51 29 Debt related fees and amortization expense 782 1,776 Subsidiary portion of net losses 25,370 91,561 Gain on litigation - (1,400 ) Warrants issued for working capital agreement 409 - Changes in assets and liabilities: Prepaid expenses (608 ) 111 Accounts payable 699 (90 ) Accrued interest expense 785 778 Other liabilities 85 (4,625 ) Other assets 276 207 Net cash used in operating activities (10,911 ) (13,001 ) Investing activities: Capital expenditures (65 ) (128 ) Subsidiary advances, net (9,707 ) 1,222 Net cash provided by (used in) investing activities (9,772 ) 1,094 Financing activities: Proceeds from the exercise of stock options 133 206 Proceeds from issuance of common stock in equity offering 21,718 11,987 Net cash provided by financing activities 21,851 12,193 Net increase in cash, cash equivalents, and restricted cash 1,168 286 Cash, cash equivalents and restricted cash at beginning of period 286 - Cash, cash equivalents, and restricted cash at end of period $ 1,454 $ 286 Supplemental disclosures of cash flow information, cash paid: Income taxes paid 7 7 Supplemental disclosures of cash flow information, non-cash transactions: Fair value of warrants issued to subordinated debt holders 1,278 1,939 Fair value of stock issued to a related party for guarantee fees - 2,012 Fair value of warrants issued for capital expenditures 318 - Fair value of warrants issued to lender for debt issuance costs - 3,158 Fair value of stock issued to lender - 1,335

Note 1 - Nature of Activities_3

Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Feb. 28, 2023 USD ($)	May 31, 2022 USD ($)	Oct. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2019 USD ($)
Number of Operating Segments						3
U.S. Department of Food And Agriculture Forest Service [Member]
Awarded Grants						$ 245
Proceeds from Grantors						166,000
LCFPP [Member]
Awarded Grants						4,200
Proceeds from Grantors						3,800
CDFAs[Member]
Awarded Grants			$ 7,800					$ 3,200
Proceeds from Grantors						6,200
CEC [Member]
Matching Contribution								7,900
Actual Expenses Incurred								5,000
Unearned Grant Proceeds						1,700	$ 1,700
CEC [Member] | Maximum [Member]
Awarded Grants								$ 5,000
California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System [Member]
Awarded Grants						8,000
Proceeds from Grantors						4,400
Matching Contribution						1,600
CAL FIRE Business and Workforce Development Grant Program [Member]
Awarded Grants		$ 2,000
Proceeds from Grantors						0
Matching Contribution		5,800
CAL Fire [Member]
Awarded Grants		500
Proceeds from Grantors						0
US Forest Service [Member]
Awarded Grants		642
USDA Bioguel Producer Program [Member]
Proceeds from Grantors					$ 14,200
Matching Contribution		$ 2,400
California Energy Commission Grant for Mechanical Vapor Recompression System [Member]
Awarded Grants						6,000
Proceeds from Grantors						0
Matching Contribution						5,300
CEC PG&E Pipeline Interconnect [Member]
Proceeds from Grantors	$ 5,000
PG&E SEM Incentive Program [Member]
Proceeds from Grantors				$ 374
Other Receivable [Member]
Accumulated Deferred Investment Tax Credit						55,200
India Biodiesel [Member] | Other Current Assets [Member]
Tax Credit Carryforward, Amount						1,600
Nontrade Receivables, Current						69
Accounts and Other Receivables, Net, Current						$ 1,200

Note 1 - Nature of Activities_4

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of America By Product Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales	$ 77,194	$ 28,111
California Ethanol [Member]
Sales	104,068	228,194
California Ethanol [Member] | Alternative Energy, Ethanol [Member]
Sales	78,403	165,876
California Ethanol [Member] | Wet Distillers Grains [Member]
Sales	21,963	50,930
California Ethanol [Member] | Product and Service, Other [Member]
Sales	3,702	11,388
California Dairy Renewable Natural Gas [Member] | Gas Molecules and RIN Credits [Member]
Sales	5,455	208
India Biodiesel [Member] | Renewable Energy, Biodiesel [Member]
Sales	74,503	27,041
India Biodiesel [Member] | Product and Service, Other [Member]
Sales	$ 2,691	$ 1,070

Note 1 - Nature of Activities_5

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	6,280	6,999
Other Current Assets [Member]
Restricted cash	289	725
Other Assets [Member]
Restricted cash	$ 3,324	$ 1,961

Note 1 - Nature of Activities_6

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	7,323	6,417
Series B Convertible Preferred Stock [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	0	127
Common Stock Options and Warrants [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	6,056	5,050
Debt with Conversion Feature [Member]
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares)	1,267	1,240

Note 1 - Nature of Activities_7

Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Debt with Conversion Feature [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 30	$ 30

Note 2 - Inventories (Details T

Note 2 - Inventories (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory Write-down	$ 58	$ 100

Note 2 - Inventories - Schedule

Note 2 - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Raw materials	$ 9,907	$ 2,971
Work-in-progress	1,682	127
Finished goods	6,702	1,560
Total inventories	$ 18,291	$ 4,658

Note 3 - Property, Plant and _3

Note 3 - Property, Plant and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Capitalized Interest Costs, Including Allowance for Funds Used During Construction	$ 5,600	$ 11,100
Depreciation	$ 6,933	$ 5,535

Note 3 - Property, Plant and _4

Note 3 - Property, Plant and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Land	$ 7,345	$ 7,344
Plant and buildings	136,318	99,116
Furniture and fixtures	2,266	1,831
Machinery and equipment	14,982	15,209
Construction in progress	73,057	88,990
Property held for development	15,431	15,437
Total gross property, plant & equipment	252,288	230,972
Less accumulated depreciation	(57,180)	(50,531)
Total net property, plant & equipment	195,108	180,441
Property, Plant and Equipment [Member]
Finance lease right of use assets	$ 2,889	$ 3,045

Note 3 - Property, Plant and _5

Note 3 - Property, Plant and Equipment - Depreciation of Property, Plant, and Equipment (Details)	Dec. 31, 2023
Minimum [Member] | Building [Member]
Useful life (Year)	20 years
Minimum [Member] | Machinery and Equipment [Member]
Useful life (Year)	5 years
Minimum [Member] | Furniture and Fixtures [Member]
Useful life (Year)	3 years
Maximum [Member] | Building [Member]
Useful life (Year)	30 years
Maximum [Member] | Machinery and Equipment [Member]
Useful life (Year)	15 years
Maximum [Member] | Furniture and Fixtures [Member]
Useful life (Year)	5 years

Note 4 - Debt (Details Textual)

Note 4 - Debt (Details Textual) $ / shares in Units, gal in Millions

Jan. 01, 2024 USD ($) $ / shares shares

Jul. 28, 2023 USD ($)

Jul. 01, 2023 USD ($) $ / shares shares

May 16, 2023 USD ($) $ / shares shares

Jan. 01, 2023 USD ($) $ / shares shares

Oct. 04, 2022 USD ($)

Mar. 02, 2022 USD ($) $ / shares shares

Mar. 06, 2020 USD ($)

Jul. 06, 2012 USD ($)

Mar. 04, 2011 USD ($)

Mar. 25, 2024 USD ($)

Mar. 22, 2024 USD ($)

Dec. 31, 2023 USD ($) $ / shares

Sep. 30, 2023 USD ($)

May 04, 2023 USD ($) gal

Mar. 31, 2023

Mar. 06, 2023 USD ($)

Dec. 31, 2022 USD ($) $ / shares

Aug. 08, 2022 USD ($)

Aug. 01, 2022 USD ($)

Jul. 26, 2022 USD ($)

May 11, 2022 USD ($)

Mar. 08, 2022 USD ($)

Dec. 31, 2021 $ / shares

Aug. 09, 2021 USD ($)

Mar. 14, 2021 USD ($)

May 01, 2020 USD ($)

Nov. 21, 2019 USD ($)

Feb. 27, 2019 $ / shares

Oct. 16, 2016 USD ($)

Jan. 09, 2012 USD ($) $ / shares

Jan. 06, 2012 USD ($)

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 11.7

$ 15.92

$ 2.59

Long-Term Debt, Total

$ 294,721,000

Warrants and Rights Outstanding, Term (Year)

5 years 9 months 7 days

7 years 5 months 23 days

4 years 11 months 12 days

Short-Term Debt

$ 23,443,000

$ 36,754,000

Debt, Long-Term and Short-Term, Combined Amount

294,721,000

246,240,000

Other Long-Term Debt, Noncurrent

51,717,000

11,678,000

Stock Issued Under Fuels Revolving Line [Member]

Stock Issued During Period, Shares, New Issues (in shares) | shares

100,000

Five Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

50,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 10.2

Ten Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

250,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 20

Warrants in Connection With Subordinated Notes [Member] | AAFK [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.01

$ 0.01

$ 0.01

Warrants and Rights Outstanding, Term (Year)

2 years

2 years

2 years

Class of Warrant or Right, Issued (in shares) | shares

113,000

113,000

Warrants in Connection With Subordinated Notes [Member] | Subsequent Event [Member] | AAFK [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

113,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.01

Warrants and Rights Outstanding, Term (Year)

2 years

Class of Warrant or Right, Issued (in shares) | shares

113

Revolving Credit Facility [Member]

Repayments of Long-Term Lines of Credit

$ 16,000,000

Property Taxes Payment

6,100,000

Capital Revolving Credit Facility Fuels And Carbon Lines [Member] | GAFI and ACCI [Member]

Line of Credit Facility, Maximum Borrowing Capacity

100,000,000

Fuels Revolving Line [Member] | GAFI [Member]

Line of Credit Facility, Maximum Borrowing Capacity

50,000,000

Carbon Revolving Line [Member] | ACCI [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 50,000,000

Third Eye Capital [Member] | Mr. McAfee [Member]

Net Amount at Risk by Product and Guarantee, Net Amount at Risk

8,000,000

Third Eye Capital [Member] | Warrants in Association With Amendment No. 27 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

80,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 2

Third Eye Capital [Member] | Revolving Credit Facility [Member]

Debt Instrument, Face Amount

$ 18,000,000

Long-Term Debt, Total

21,900,000

Debt Issuance Costs, Net

$ 900,000

Third Eye Capital [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]

Debt Instrument, Interest Rate, Stated Percentage

22.25%

Debt Instrument, Basis Spread on Variable Rate

13.75%

Third Eye Capital [Member] | Acquisition Term Notes [Member]

Debt Instrument, Face Amount

$ 15,000,000

Third Eye Capital [Member] | Revolving Notes Series B [Member]

Long-Term Debt, Total

$ 54,800,000

Debt Issuance Costs, Net

$ 400,000

Third Eye Capital [Member] | Revolving Notes Series B [Member] | Prime Rate [Member]

Debt Instrument, Interest Rate, Stated Percentage

22.25%

Debt Instrument, Basis Spread on Variable Rate

13.75%

Third Eye Capital [Member] | Reserve Liquidity Facility [Member]

Line of Credit Facility, Current Borrowing Capacity

$ 85,000,000

Debt Instrument, Interest Rate, Stated Percentage

30%

Long-Term Debt, Total

$ 0

Term Loan [Member] | Third Eye Capital [Member]

Debt Instrument, Face Amount

7,200,000

Revenue Participation Term Notes [Member] | Third Eye Capital [Member]

Debt Instrument, Face Amount

$ 10,000,000

Debt Instrument, Interest Rate, Stated Percentage

5%

Revenue Participation Term Notes [Member] | Third Eye Capital [Member] | AAFK [Member]

Long-Term Debt, Total

$ 12,100,000

Debt Issuance Costs, Net

$ 81,000

Amendment No. 22 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 100,000

Amendment No. 23 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 100,000

Amendment No. 24 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 300,000

Debt Instrument, Extension Fee, Percent of Note Indebtedness

1%

Amendment No. 25 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 100,000

Amendment No. 26 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 100,000

Debt Instrument, Minimum Production Requirement (Gallon) | gal

10

Amendment No. 27 [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 500,000

Debt Instrument, Extension Fee, Percent of Note Indebtedness

1%

Amendment No 28 [Member] | Third Eye Capital [Member] | Subsequent Event [Member]

Debt Instrument, Fee Amount

$ 100,000

Reserve Liquidity Facility [Member] | Third Eye Capital [Member]

Debt Instrument, Face Amount

$ 18,000,000

Debt Instrument, Term (Year)

1 year

Line of Credit Facility, Maximum Borrowing Capacity

$ 70,000,000

Line of Credit Facility, Current Borrowing Capacity

$ 40,000,000

Debt Instrument, Non-refundable Standby Fee, Percent of Difference Between Principal Amount and the Commitment

2%

Non Refundable Fees

$ 500,000

Reserve Liquidity Facility [Member] | Third Eye Capital [Member] | Subsequent Event [Member]

Debt Instrument, Fee Amount

500,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 85,000,000

$ 85,000,000

Reserve Liquidity Facility Paid Monthly in Arrears [Member] | Third Eye Capital [Member]

Debt Instrument, Interest Rate, Stated Percentage

30%

Reserve Liquidity Facility if Event of Default Occurred and Continues [Member] | Third Eye Capital [Member]

Debt Instrument, Interest Rate, Stated Percentage

40%

Term Notes [Member] | Third Eye Capital [Member]

Debt Instrument, Interest Rate, Stated Percentage

14%

Long-Term Debt, Total

$ 7,200,000

Debt Issuance Costs, Net

45,000

Acquisition Term Notes [Member] | Third Eye Capital [Member]

Long-Term Debt, Total

26,800,000

Debt Issuance Costs, Net

184,000

Acquisition Term Notes [Member] | Third Eye Capital [Member] | Aemetis Facility Keyes, Inc. [Member]

Debt Instrument, Redemption Fee

$ 7,500,000

Acquisition Term Notes [Member] | Third Eye Capital [Member] | Prime Rate [Member]

Debt Instrument, Interest Rate, Stated Percentage

19.25%

Debt Instrument, Basis Spread on Variable Rate

10.75%

Fuels Revolving Line [Member] | GAFI [Member]

Debt Instrument, Interest Rate, Stated Percentage

10%

14.50%

Long-Term Debt, Total

$ 33,900,000

Debt Issuance Costs, Net

$ 1,300,000

Fuels Revolving Line [Member] | Prime Rate [Member] | GAFI [Member]

Debt Instrument, Basis Spread on Variable Rate

6%

Carbon Revolving Line [Member] | ACCI [Member]

Debt Instrument, Interest Rate, Stated Percentage

8%

12.50%

Long-Term Debt, Total

$ 25,200,000

Debt Issuance Costs, Net

1,700,000

Carbon Revolving Line [Member] | Prime Rate [Member] | ACCI [Member]

Debt Instrument, Basis Spread on Variable Rate

4%

Cilion Shareholder Seller Notes Payable [Member]

Debt Instrument, Face Amount

$ 5,000,000

Debt Instrument, Interest Rate, Stated Percentage

3%

Long-Term Debt, Total

7,000,000

Debt, Long-Term and Short-Term, Combined Amount

7,028,000

6,821,000

Subordinated Notes [Member] | AAFK [Member]

Debt Instrument, Fee Amount

$ 2,500,000

$ 900,000

Debt Instrument Fee Rate

10%

Debt Extension Fee, Percentage

10%

Short-Term Debt

17,600,000

15,900,000

Subordinated Notes 1 [Member]

Short-Term Debt

17,625,000

15,931,000

Subordinated Notes 1 [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 90,000

$ 90,000

Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 90,000

Subordinated Notes 2 [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 250,000

$ 250,000

Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 250,000

EB5 Phase I Notes [Member]

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Term (Year)

4 years

Long-Term Debt, Total

37,900,000

Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares

$ 30

Debt Instrument, Amount Released From Escrow

35,500,000

Debt Instrument, Amount Remaining Funded to Escrow

500,000

EB5 Phase I Notes [Member] | Scenario, Plan [Member]

Debt Instrument, Face Amount

$ 50,000,000

EB5 Phase I Notes [Member] | Minimum [Member]

Debt Instrument, Investment Raised Per Investor

$ 500,000

EB5 Phase I Funding [Member]

Debt Instrument, Face Amount

$ 36,000,000

EB5 Phase I Funding [Member] | Maximum [Member]

Debt Instrument, Face Amount

$ 36,000,000

EB5 Phase II Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

3%

Debt Instrument, Amount Remaining Funded to Escrow

46,800,000

Debt Instrument, Principal Amount Sold

4,000,000

Debt, Long-Term and Short-Term, Combined Amount

4,300,000

EB5 Phase II Notes [Member] | Maximum [Member]

Debt Instrument, Minimum Investment Raised Per Investor

$ 900,000

Debt Instrument, Investment Raised Per Investor

900,000

Aggregate Principal Amount

$ 50,800,000

EB5 Phase II Notes [Member] | Minimum [Member]

Debt Instrument, Minimum Investment Raised Per Investor

$ 500,000

Secunderabad Oils [Member]

Debt Instrument, Interest Rate, Stated Percentage

18%

Short-Term Debt

3,800,000

0

Debt Agreement, Maximum Borrowing Capacity

$ 1,880,000

Leo Edibles & Fats Limited [Member]

Debt Agreement, Maximum Borrowing Capacity

$ 1,270,000

IndusInd Bank and HDFC Bank Secured Loans [Member]

Short-Term Debt

0

0

IndusInd Bank and HDFC Bank Secured Loans [Member] | Maximum [Member]

Debt Instrument, Interest Rate, Stated Percentage

8%

IndusInd Bank and HDFC Bank Secured Loans [Member] | Minimum [Member]

Debt Instrument, Interest Rate, Stated Percentage

6%

Construction Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

9.25%

Long-Term Debt, Total

25,100,000

0

Debt, Long-Term and Short-Term, Combined Amount

41,024,000

19,820,000

Debt Agreement, Maximum Borrowing Capacity

$ 25,000,000

Construction Loan Agreement [Member] | US Treasury (UST) Interest Rate [Member]

Debt Instrument, Basis Spread on Variable Rate

5%

Construction Loan Agreement 2 [Member]

Debt Instrument, Interest Rate, Stated Percentage

8.75%

Long-Term Debt, Total

16,800,000

0

Debt Issuance Costs, Net

800,000

$ 0

Debt Agreement, Maximum Borrowing Capacity

$ 25,000,000

Construction Loan Agreement 2 [Member] | US Treasury (UST) Interest Rate [Member]

Debt Instrument, Basis Spread on Variable Rate

5%

Financing Agreement For Capital Expenditures [Member]

Debt Instrument, Face Amount

$ 5,700,000

Short-Term Debt

2,000,000

Other Long-Term Debt, Noncurrent

$ 3,800,000

Note 4 - Debt- Schedule of Debt

Note 4 - Debt- Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt, Long-Term and Short-Term, Combined Amount	$ 294,721	$ 246,240
Short-Term Debt	23,443	36,754
Less current portion of debt	37,028	49,219
Total long term debt	257,693	197,021
Third Eye Capital Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	7,159	7,141
Third Eye Capital Revolving Credit Facility [Member]
Debt, Long-Term and Short-Term, Combined Amount	20,922	60,602
Revolving Notes Series B [Member]
Debt, Long-Term and Short-Term, Combined Amount	54,412	0
Third Eye Capital Revenue Participation Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	12,011	11,963
Third Eye Capital Acquisition Term Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	26,655	26,578
Third Eye Capital Fuels Revolving Line [Member]
Debt, Long-Term and Short-Term, Combined Amount	32,511	27,410
Third Eye Capital Carbon Revolving Line [Member]
Debt, Long-Term and Short-Term, Combined Amount	23,486	22,710
Construction Loan Agreement [Member]
Debt, Long-Term and Short-Term, Combined Amount	41,024	19,820
Cilion Shareholder Seller Notes Payable [Member]
Debt, Long-Term and Short-Term, Combined Amount	7,028	6,821
Subordinated Notes 1 [Member]
Short-Term Debt	17,625	15,931
EB-5 Promissory Notes [Member]
Debt, Long-Term and Short-Term, Combined Amount	42,211	41,404
Working capital Loan [Member]
Short-Term Debt	3,827	0
Term Loan On Equipment Purchase [Member]
Debt, Long-Term and Short-Term, Combined Amount	$ 5,850	$ 5,860

Note 4 - Debt - Maturities of L

Note 4 - Debt - Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 37,028
2025	181,464
2026	37,912
2027	4,128
2028	2,108
There after	37,545
Total debt	300,185
Debt issuance costs	(5,464)
Total debt, net of debt issuance costs	$ 294,721

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	May 06, 2022	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 24, 2019
Estimated Litigation Liability, Current					$ 6,200
Litigation Settlement, Amount Awarded to Other Party	$ 4,800
Gain (Loss) Related to Litigation Settlement		$ 1,400	$ 0	$ 1,400
Payments for Legal Settlements		$ 4,800
Minimum [Member]
Lease Term (Year)			1 year
Maximum [Member]
Lease Term (Year)			13 years

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease expense	$ 722	$ 673
Short term lease expense	223	176
Variable lease expense	93	91
Total operating lease cost	1,038	940
Amortization of right-of-use assets	121	179
Interest on lease liabilities	340	310
Total finance lease cost	461	489
Operating cash flows used in operating leases	668	766
Operating cash flows used in finance leases	340	310
Financing cash flows used in finance leases	$ 428	$ 481

Note 5 - Commitments and Cont_5

Note 5 - Commitments and Contingencies - Non-cash Flow Information Related to ROU Asset and Lease Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accretion of the lease liability	$ 249	$ 340
Amortization of right-of-use assets	$ 293	$ 333
Operating leases (in years) (Year)	4 years 2 months 12 days	5 years 2 months 12 days
Finance leases (in years) (Year)	13 years	14 years
Operating leases	14.10%	14.20%
Finance leases	13.20%	13.20%

Note 5 - Commitments and Cont_6

Note 5 - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating lease right-of-use assets	$ 2,056	$ 2,449
Current portion of operating lease liability	406	338
Operating lease liability	1,783	2,189
Total operating lease liabilities	2,189	2,527
Total finance lease liabilities	2,717
Property, Plant and Equipment [Member]
Property and equipment, at cost	2,889	3,045
Accumulated depreciation	(228)	(112)
Property and equipment, net	2,661	2,933
Other Current Liabilities [Member]
Other current liability	30	71
Other Noncurrent Liabilities [Member]
Other long term liabilities	2,687	2,911
Other Liabilities [Member]
Total finance lease liabilities	$ 2,717	$ 2,982

Note 5 - Commitments and Cont_7

Note 5 - Commitments and Contingencies - Maturities of Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024, Operating leases	$ 682
2024, Finance leases	179
2025, Operating leases	681
2025, Finance leases	168
2026, Operating leases	626
2026, Finance leases	145
2027, Operating leases	645
2027, Finance leases	145
2028, Operating leases	272
2028, Finance leases	145
Thereafter, Operating leases	0
Thereafter, Finance leases	10,105
Total lease payments, Operating leases	2,906
Total lease payments, Finance leases	10,887
Less imputed interest, Operating leases	(717)
Less imputed interest, Finance leases	(8,170)
Total operating lease liability	2,189	$ 2,527
Total finance lease liability	$ 2,717

Note 5 - Commitments and Cont_8

Note 5 - Commitments and Contingencies - Lease Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease income	$ 2,075	$ 1,255

Note 5 - Commitments and Cont_9

Note 5 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 948
2025	773
2026	562
2027	508
2028	508
There after	635
Total future lease commitments	$ 3,934

Note 6 - Aemetis Biogas - Ser_2

Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity (Details Textual) - USD ($)

12 Months Ended

14 Months Ended

15 Months Ended

17 Months Ended

44 Months Ended

Nov. 08, 2023

Oct. 06, 2023

Aug. 31, 2023

May 31, 2023

Feb. 08, 2023

Jan. 01, 2023

Aug. 08, 2022

Dec. 20, 2018

Dec. 31, 2023

Dec. 31, 2022

Dec. 24, 2024

Aug. 31, 2024

May 31, 2024

Aug. 08, 2022

Feb. 08, 2024

Payments for Repurchase of Redeemable Convertible Preferred Stock

$ 30,000,000

$ 0

Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent

113,200,000

116,000,000

Assets

243,406,000

207,114,000

California Dairy Renewable Natural Gas [Member]

Assets

92,794,000

77,714,000

California Dairy Renewable Natural Gas [Member] | Asset Pledged as Collateral [Member] | Aemetis Biogas LLC [Member] | Preferred Units Series A [Member]

Assets

$ 90,300,000

Carbon Revolving Line [Member]

Extinguishment of Debt, Gain (Loss), Net of Tax

$ (49,400,000)

Common Units [Member]

Common Stock, Capital Shares Reserved for Future Issuance (in shares)

5,000,000

Preferred Units Series A [Member]

Common Units Authorized (in shares)

11,000,000

Preferred Units, Authorized (in shares)

6,000,000

Preferred Unit Dividend Rate Per Dollar Amount (in dollars per share)

$ 0.5

Conversion of Stock, Shares Issued (in shares)

1,200,000

5,000,000

Maximum Number of Shares (in shares)

5,000,000

Redeemable Noncontrolling Interest, Equity, Preferred, Redemption Value per Unit (in dollars per share)

$ 15

Free Cash Flow Generated by ABGL

75%

100%

Redeemable Noncontrolling Interest Equity Redemption Value, Total

$ 90,000,000

Fees and Commission Transfer Agent

900,000

Debt Instrument, Collateral Amount

$ 30,000,000

Preferred Units Series A [Member] | First Tranche [Member]

Preferred Units, Issued (in shares)

3,200,000

3,200,000

Preferred Units Issued Value

$ 16,000,000

Preferred Units Series A [Member] | Second Tranche [Member

Preferred Units, Issued (in shares)

2,800,000

2,800,000

Preferred Units Issued Value

$ 14,000,000

Stock Redeemed or Called During Period, Shares (in shares)

20,000

Preferred Units Redeemed, Value

$ 300,000

Preferred Units Series A [Member] | Third Eye Capital [Member]

Sale of Stock, Number of Shares Issued in Transaction (in shares)

6,000,000

Series A Preferred Stocks [Member]

Common Units Issued (in shares)

6,000,000

Common Units Issuance Value (in dollars per share)

$ 5

Proceeds from Issuance of Common Units

$ 30,000,000

PUPA Second Amendment [Member]

Preferred Units Issued Value

$ 116,000,000

$ 116,000,000

PUPA Second Amendment [Member] | Forecast [Member]

Preferred Units Issued Value

$ 159,000,000

PUPA Second Amendment [Member] | ABGL [Member]

Preferred Units Issued Value

$ 125,000,000

$ 106,000,000

PUPA Third Amendment [Member]

Preferred Units Issued Value

$ 127,200,000

Payments for Repurchase of Redeemable Convertible Preferred Stock

$ 30,000,000

Proceeds from Sale of Income Tax Credits

$ 55,200,000

PUPA Third Amendment [Member] | Forecast [Member]

Preferred Units Issued Value

$ 171,700,000

PUPA Third Amendment [Member] | ABGL [Member]

Preferred Units Issued Value

$ 135,000,000

PUPA Fourth Amendment [Member]

Preferred Units Issued Value

$ 110,600,000

Preferred Stock, Redemption Amount

108,000,000

Closing Fee

$ 5,500,000

PUPA Fourth Amendment [Member] | Subsequent Event [Member]

Closing Fee

$ 5,500,000

PUPA Fourth Amendment [Member] | Forecast [Member]

Increase in Carrying Amount of Redeemable Preferred Stock

$ 130,000,000

PUPA Fifth Amendment [Member]

Preferred Units Issued Value

$ 111,000,000

PUPA Fifth Amendment [Member] | Subsequent Event [Member]

Preferred Stock, Redemption Amount

$ 111,000,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common Stock, Shares Authorized (in shares)	80,000,000	80,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Preferred Units, Authorized (in shares)	65,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	10
Preferred Stock, Shares Outstanding (in shares)	0

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Schedule of Stock by Class (Details) - shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Series B Preferred Stock, Authorized (in shares)	65,000
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Series B Preferred Stock [Member]
Series B Preferred Stock, Authorized (in shares)	7,235
Series B Preferred Stock, Shares Issued (in shares)	0	1,270
Undesignated [Member]
Series B Preferred Stock, Authorized (in shares)	57,765
Series B Preferred Stock, Shares Issued (in shares)	0	0

Note 8 - Warrants to Purchase_3

Note 8 - Warrants to Purchase Common Stocks (Details Textual) - $ / shares	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 11.7	$ 15.92	$ 2.59
Warrants and Rights Outstanding, Term (Year)	5 years 9 months 7 days	7 years 5 months 23 days	4 years 11 months 12 days
Warrants to Purchase Common Stock [Member] | Vendor [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.5
Warrants and Rights Outstanding, Term (Year)	2 years
Stock Issued During Period, Warrants Exercised (in shares)	62,293
Warrants to Purchase Common Stock [Member] | Senior Lenders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	160,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants to Purchase Common Stock, Modification [Member] | Senior Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 10.2
Warrants and Rights Outstanding, Term (Year)	3 years
Class of Warrant or Right, Number of Additional Securities Called by Warrants or Rights (in shares)	25,000
Warrants Issued to Subordinated Debt Holders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	226,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01
Warrants and Rights Outstanding, Term (Year)	2 years

Note 8 - Warrants to Purchase_4

Note 8 - Warrants to Purchase Common Stock - Fair Value Assumptions (Details)	Dec. 31, 2023 $ / shares yr	Dec. 31, 2022 $ / shares yr
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0385	0.0175
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.179	1.5141
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	5	3
Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.62	10.47
Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	4.13	11.29
Fair Value per Warrant on Grant Date [Member]
Warrants and Rights Outstanding, Measurement Input	3.92	9.68

Note 8 - Warrants to Purchase_5

Note 8 - Warrants to Purchase Common Stock - Schedule of Warrants or Rights (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Outstanding, warrants (in shares)	355	55
Outstanding, Weighted - Average Exercise Price (in dollars per share)	$ 15.92	$ 2.59
Outstanding, Average Remaining Term in Years (Year)	5 years 9 months 7 days	7 years 5 months 23 days	4 years 11 months 12 days
Granted, warrants (in shares)	511	527
Granted, Weighted - Average Exercise Price (in dollars per share)	$ 1.62	$ 10.47
Exercised, warrants (in shares)	(336)	(227)
Exercised, Weighted - Average Exercise Price (in dollars per share)	$ 0.83	$ 0.01
Outstanding, warrants (in shares)	530	355
Outstanding, Weighted - Average Exercise Price (in dollars per share)	$ 11.7	$ 15.92

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Aug. 26, 2021	Apr. 25, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Jul. 01, 2021	Mar. 31, 2016
Share Price (in dollars per share)			$ 5.24	$ 3.96
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			5,526,000	4,694,000
Share-Based Payment Arrangement, Expense			$ 7.7	$ 6.4
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 7.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 6 months
The 2019 Stock Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							4,558,621
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage Increase in Shares Available for Issuance Based on Common stock Outstanding	4%
Share-Based Compensation Arrangement by Share-Based Payment Award, Measurement Input, Shares (in shares)	2,541,823
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			244,000
Share Price (in dollars per share)			$ 3.6	$ 10.97
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			5,526,000	4,694,000		3,763,000
The 2019 Stock Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				89,000
The 2019 Stock Plan [Member] | Restricted Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			244,000	89,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in dollars per share)			$ 3.75	$ 10.92
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)			1,300,000	1,300,000
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
Inducement Equity Plan Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)								100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)			0

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Schedule of Share-based Payment Award (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance, outstanding (in shares)	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.63
Balance, outstanding (in shares)	5,526	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.42	$ 4.63
The 2019 Stock Plan [Member]
Balance, Shares Available for Grant (in shares)	65	42
Balance, outstanding (in shares)	4,694	3,763
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.63	$ 2.29
Authorized, shares (in shares)	1,644	1,338
Options Granted, shares (in shares)	(1,278)	(1,307)
Options Granted, shares (in shares)	1,278	1,307
Options Granted, Weighted-Average Exercise Price (in dollars per share)	$ 3.6	$ 10.97
RSAs Granted, shares (in shares)	(244)
Exercised, outstanding (in shares)	(177)	(295)
Exercised, Weighted-Average Exercise Price (in dollars per share)	$ 1.83	$ 0.93
Forfeited/expired, shares available (in shares)	269	81
Forfeited/expired, outstanding (in shares)	(269)	(81)
Forfeited/expired, Weighted-Average Exercise Price (in dollars per share)	$ 5.93	$ 11.63
Balance, Shares Available for Grant (in shares)	456	65
Balance, outstanding (in shares)	5,526	4,694
Balance, Weighted-Average Exercise Price (in dollars per share)	$ 4.42	$ 4.63
The 2019 Stock Plan [Member] | Restricted Stock [Member]
RSAs Granted, shares (in shares)		(89)

Note 9 - Stock-Based Compensa_5

Note 9 - Stock-Based Compensation - Share-Based Compensation Arrangement by Share-Based Payment Award, Options Vested and Expected to Vest, Outstanding, and Exercisable (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		24 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Vested and Exercisable, number of shares (in shares)		3,986	3,170
Vested and Exercisable, weighted average exercise price (in dollars per share)		$ 3.58	$ 2.46
Vested and Exercisable, remaining contractual term (Year)		6 years 5 months 19 days	6 years 11 months 23 days
Vested and Exercisable, aggregate intrinsic value	[1]	$ 11,695	$ 7,419
Unvested, number of share (in shares)		1,540	1,524
Unvested, weighted average exercise price (in dollars per share)		$ 6.55	$ 9.13
Unvested, remaining contractual term (Year)		8 years 8 months 1 day	8 years 9 months 21 days
Unvested, aggregate intrinsic value	[1]	$ 1,621	$ 647
Number of shares (in shares)		5,526	4,694
Weighted average exercise price (in dollars per share)		$ 4.42	$ 4.63
Remaining contractual term (Year)		7 years 14 days	7 years 6 months 29 days
Aggregate intrinsic value	[1]	$ 13,316	$ 8,066
[1]Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 and 2022 respectively, as reported on the NASDAQ Exchange.

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Fair Value Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Market value per share on grant date (in dollars per share)	$ 5.24	$ 3.96
The 2019 Stock Plan [Member]
Dividend-yield	0%	0%
Risk-free interest rate	3.86%	2.03%
Expected volatility	124.62%	117.21%
Expected life (years) (Year)	7 years	7 years
Market value per share on grant date (in dollars per share)	$ 3.6	$ 10.97
Fair value per share on grant date (in dollars per share)	$ 3.29	$ 9.71

Note 10 - Agreements (Details T

Note 10 - Agreements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jul. 01, 2022
Prepaid Expense, Current	$ 3,347	$ 4,248
Marketing Expense	1,500	2,900
Shipping and Handling Costs	1,700	3,300
Results of Operations, Transportation Costs	3,300	5,300
Forward Sales Commitments [Member]
Other Commitment	0
Operating Agreement with Gemini Edibles and Fats India Private Limited [Member]
Debt Agreement, Maximum Borrowing Capacity			$ 12,700
Debt Instrument, Interest Rate, Stated Percentage			12%
Accounts Payable	0	0
J.D. Heiskell [Member]
Prepaid Expense, Current	$ 0	$ 2,400

Note 10 - Agreements - Schedule

Note 10 - Agreements - Schedule of Working Capital Agreement Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Accounts payable	32,132	26,168
J.D. Heiskell [Member]
Accounts receivable	1,073	0
Accounts payable	1,207	27
Ethanol Sales [Member] | J.D. Heiskell [Member]
Revenues	77,359	0
Wet Distiller's Grains Sales [Member] | J.D. Heiskell [Member]
Revenues	21,963	50,930
CDO and CDS [Member] | J.D. Heiskell [Member]
Revenues	3,296	10,168
Corn Purchases [Member] | J.D. Heiskell [Member]
Corn purchases	$ 83,128	$ 191,401

Note 11 - Segment Information_2

Note 11 - Segment Information (Details Textual) gal in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2023 gal	Dec. 31, 2022
Number of Reportable Segments		3
California Ethanol [Member]
GallonPerYear (Gallon)		65
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member]
Number of Major Customers		1	1
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member] | Customer One [Member]
Concentration Risk, Percentage		100%
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member]
Number of Major Customers			1
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer One [Member]
Concentration Risk, Percentage			73%
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer Two [Member]
Concentration Risk, Percentage			26%
India Biodiesel [Member]
GallonPerYear (Gallon)		60
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer One [Member]
Concentration Risk, Percentage		47%	48%
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Two [Member]
Concentration Risk, Percentage		25%	29%
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Three [Member]
Concentration Risk, Percentage		23%	12%
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member]
Number of Major Customers		1
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member] | Customer One [Member]
Concentration Risk, Percentage		100%
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member]
Number of Major Customers	1
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member] | Customer One [Member]
Concentration Risk, Percentage	98%

Note 11 - Segment Information -

Note 11 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Gross profit (loss)	2,017	(5,535)
Interest expense, including amortization of debt fees	39,519	28,770
Accretion and other expenses of Series A preferred units	25,313	9,888
Income tax expense (benefit)	(53,736)	1,053
Capital expenditures	33,119	39,157
Depreciation	6,933	5,535
Total Assets	243,406	207,114
Loss on debt extinguishment	0	49,386
Intersegment Eliminations [Member]
Revenues	0	1,002
California Ethanol [Member]
Revenues	104,068	228,194
Gross profit (loss)	(6,602)	(13,017)
Interest expense, including amortization of debt fees	25,258	20,637
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	0	0
Capital expenditures	5,695	8,399
Depreciation	3,995	4,148
Total Assets	67,991	66,794
Loss on debt extinguishment		0
California Ethanol [Member] | Intersegment Eliminations [Member]
Revenues	0	0
California Dairy Renewable Natural Gas [Member]
Revenues	5,455	208
Gross profit (loss)	(331)	(778)
Interest expense, including amortization of debt fees	2,809	742
Accretion and other expenses of Series A preferred units	25,313	9,888
Income tax expense (benefit)	(55,159)	6
Capital expenditures	24,744	22,884
Depreciation	2,116	615
Total Assets	92,794	77,714
Loss on debt extinguishment		49,386
California Dairy Renewable Natural Gas [Member] | Intersegment Eliminations [Member]
Revenues	0	1,002
India Biodiesel [Member]
Revenues	77,194	28,111
Gross profit (loss)	8,950	8,273
Interest expense, including amortization of debt fees	447	119
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	1,416	1,040
Capital expenditures	1,281	129
Depreciation	576	650
Total Assets	34,769	16,120
Loss on debt extinguishment		0
India Biodiesel [Member] | Intersegment Eliminations [Member]
Revenues	0	0
Other Segments [Member]
Revenues	0	0
Gross profit (loss)	0	(13)
Interest expense, including amortization of debt fees	11,005	7,272
Accretion and other expenses of Series A preferred units	0	0
Income tax expense (benefit)	7	7
Capital expenditures	1,399	7,745
Depreciation	246	122
Total Assets	47,852	46,486
Loss on debt extinguishment		0
Other Segments [Member] | Intersegment Eliminations [Member]
Revenues	$ 0	$ 0

Note 11 - Segment Information_3

Note 11 - Segment Information - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 186,717	$ 256,513
Elimination of intersegment revenues	0	(1,002)
Operating Segments [Member]
Revenues	$ 186,717	$ 257,515

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expense	$ 7,700	$ 6,400
Mr. McAfee [Member]
Accrued Liabilities, Current	175
Various Board Members [Member]
Share-Based Payment Arrangement, Expense	400	400
Employment Agreements and Expense Reimbursements [Member] | Mr. McAfee [Member]
Related Party Transaction, Amounts of Transaction	400
Accrued Liabilities	400
One-time Guarantee Fee [Member] | Mr. McAfee [Member]
Related Party Transaction, Amounts of Transaction	350
Board Compensation Fees [Member] | Various Board Members [Member]
Related Party Transaction, Amounts of Transaction	$ 300	$ 300

Note 13 - Income Tax (Details T

Note 13 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Liabilities, Net, Total	$ 735	$ 810
Undistributed Earnings of Foreign Subsidiaries	1,300	$ 2,500
Alcohol and Cellulosic Biofuel Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,500
Carbon Oxide Sequestration Credit Carryforward [Member]
Tax Credit Carryforward, Amount	6,700
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 253,000
Domestic Tax Authority [Member] | Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
Domestic Tax Authority [Member] | Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2043
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 336,000
State and Local Jurisdiction [Member] | Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
State and Local Jurisdiction [Member] | Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2042

Note 13 - Income Tax - Schedule

Note 13 - Income Tax - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal tax expense, current	$ (55,164)	$ 0
State and Local tax expense, current	13	13
Foreign tax expense, current	1,489	230
Total tax expense, current	(53,662)	243
Federal tax expense, deferred	0	0
State and Local tax expense, deferred	0	0
Foreign tax expense, deferred	(74)	810
Income tax (benefit) expense	$ (53,736)	$ 1,053

Note 13 - Income Tax - Schedu_2

Note 13 - Income Tax - Schedule of Income Before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
United States	$ (107,191)	$ (112,959)
Foreign	7,035	6,254
Loss before income taxes	$ (100,156)	$ (106,705)

Note 13 - Income Tax - Schedu_3

Note 13 - Income Tax - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income tax benefit at the federal statutory rate	$ (21,033)	$ (22,408)
State tax benefit	(999)	(496)
Sale of tax credits	(55,164)	0
Foreign tax differential	11	168
Stock-based compensation	2,048	295
Interest Expense	92	58
GILTI Inclusion	0	1,126
Prior year true-ups	(18,031)	55
Non-includible US Entities	0	13,499
Other	67	46
Credits	(869)	(2,373)
Valuation Allowance	40,142	11,083
Income tax (benefit) expense	$ (53,736)	$ 1,053
Effective Tax Rate	53.65%	(0.99%)

Note 13 - Income Tax - Schedu_4

Note 13 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organizational Costs, Start-up and Intangible Assets	$ 34,217	$ 2,309
Stock Based Compensation	1,239	1,842
NOLs, Unabsorbed Depreciation and R&D Credits C/F's	67,621	68,201
Interest expense carryover	29,066	22,374
Accrued Expenses	2,249	2,001
Operating Lease Liability	1,282	1,512
Other, net	248	113
Total Deferred Tax Assets	144,118	105,679
Valuation Allowance	(135,354)	(95,214)
Net Deferred Tax Assets	8,764	10,465
Right of Use Asset	(1,230)	(1,477)
Property, Plant & Equipment	(8,266)	(9,788)
Other, net	(3)	(10)
Total Deferred Tax Liabilities	(9,499)	(11,275)
Net Deferred Tax Liabilities	(735)	(810)
Ethanol Credits [Member]
Deffered tax assets, tax credit carryforwards	1,500	1,500
Carbon Oxide Sequestration Credit Carryforward [Member]
Deffered tax assets, tax credit carryforwards	$ 6,696	$ 5,827

Note 13 - Income Tax - Open Tax

Note 13 - Income Tax - Open Tax Years by Major Tax Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2023
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Open tax year	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
State and Local Jurisdiction [Member]
Open tax year	2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Foreign Tax Authority [Member] | Ministry of Finance, India [Member]
Open tax year	2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Foreign Tax Authority [Member] | Mauritius Revenue Authority [Member]
Open tax year	2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Note 14 - Parent Company Fina_3

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 2,667	$ 4,313
Prepaid expenses	3,347	4,248
Other current assets	3,462	3,653
Total current assets	36,400	18,136
Property, plant and equipment, net	195,108	180,441
Total Assets	243,406	207,114
Accounts payable	32,132	26,168
Other current liabilities	10,302	8,474
Total current liabilities	84,389	88,281
Operating lease liability	2,189	2,527
Total long term liabilities	375,994	320,687
Common stock	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities & stockholders' deficit	243,406	207,114
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Mandatorily redeemable Series B convertible preferred	4,521	4,082
Parent Company [Member]
Cash and cash equivalents	1,454	286
Receivables due from subsidiaries	110,083	98,780
Prepaid expenses	437	611
Other current assets	12	7
Total current assets	111,986	99,684
Investment in subsidiary, net of advances	14,499	8,106
Property, plant and equipment, net	149	135
Other assets	2,096	2,377
Total Assets	128,730	110,302
Accounts payable	3,633	2,934
Other current liabilities	5,031	4,269
Total current liabilities	13,185	11,285
Operating lease liability	1,716	2,047
Subsidiary obligation in excess of investment	330,806	298,824
Total long term liabilities	332,522	300,871
Common stock	41	36
Additional paid-in capital	264,058	232,546
Accumulated deficit	(475,405)	(428,985)
Accumulated other comprehensive loss	(5,671)	(5,452)
Total stockholders' deficit	(216,977)	(201,854)
Total liabilities & stockholders' deficit	128,730	110,302
Parent Company [Member] | Series B Preferred Stock [Member]
Series B Preferred convertible stock	0	1
Parent Company [Member] | Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member]
Mandatorily redeemable Series B convertible preferred	4,521	4,082
Parent Company [Member] | Aemetis Property Keyes, Inc. [Member]
Investment in subsidiary, net of advances	1,556	1,274
Parent Company [Member] | Aemetis International, Inc. [Member]
Investment in subsidiary, net of advances	12,059	6,659
Parent Company [Member] | Aemetis Advanced Products Riverbank, Inc. [Member]
Investment in subsidiary, net of advances	638	173
Parent Company [Member] | AE Advanced Products Keyes, Inc. [Member]
Investment in subsidiary, net of advances	246	0
Subsidiary obligation in excess of investment	0	270
Parent Company [Member] | AE Advanced Fuels, Inc. [Member]
Subsidiary obligation in excess of investment	220,571	177,856
Parent Company [Member] | Aemetis Americas, Inc. [Member]
Subsidiary obligation in excess of investment	202	205
Parent Company [Member] | Aemetis Biofuels, Inc. [Member]
Subsidiary obligation in excess of investment	2,721	2,738
Parent Company [Member] | Aemetis Technologies, Inc. [Member]
Subsidiary obligation in excess of investment	4,868	4,716
Parent Company [Member] | Aemetis Health Products, Inc. [Member]
Subsidiary obligation in excess of investment	2,084	2,076
Parent Company [Member] | Goodland Advanced Fuels, Inc. [Member]
Subsidiary obligation in excess of investment	22,982	16,869
Parent Company [Member] | Aemetis Biogas LLC [Member]
Subsidiary obligation in excess of investment	70,471	91,292
Parent Company [Member] | Aemetis Carbon Capture, Inc. [Member]
Subsidiary obligation in excess of investment	5,895	2,323
Parent Company [Member] | Aemetis Properties Riverbank, Inc. [Member]
Subsidiary obligation in excess of investment	$ 1,012	$ 479

Note 14 - Parent Company Fina_4

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Selling, general and administrative expenses	$ 39,266	$ 28,686
Operating loss	(37,401)	(34,401)
Interest expense	39,519	28,770
Debt related fees and amortization expense	6,524	7,363
Other income	(2,077)	(14,340)
Income tax expense (benefit)	(53,736)	1,053
Net loss	(46,420)	(107,758)
Comprehensive loss	(46,639)	(108,860)
Parent Company [Member]
Equity in subsidiary losses	(25,370)	(91,561)
Selling, general and administrative expenses	19,218	15,203
Operating loss	(44,588)	(106,764)
Interest expense	1,073	806
Debt related fees and amortization expense	781	1,581
Other income	(30)	(1,400)
Loss before income taxes	(46,412)	(107,751)
Income tax expense (benefit)	8	7
Net loss	(46,420)	(107,758)
Foreign currency translation adjustment	(219)	(1,102)
Comprehensive loss	$ (46,639)	$ (108,860)

Note 14 - Parent Company Fina_5

Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Net loss		$ (46,420)	$ (107,758)
Share-based compensation		7,660	6,410
Depreciation		6,933	5,535
Debt related fees and amortization expense		6,524	7,363
Gain on litigation	$ (1,400)	0	(1,400)
Warrants issued for working capital agreement		409	0
Prepaid expenses		(1,838)	(1,777)
Accounts payable		13,726	2,183
Accrued interest expense		23,558	15,501
Other liabilities		(1,757)	(10,125)
Net cash provided by (used in) operating activities		13,825	(22,866)
Capital expenditures		(33,119)	(39,157)
Net cash used in investing activities		(23,687)	(31,306)
Proceeds from the exercise of stock options		133	206
Proceeds from issuance of common stock in equity offering		21,718	11,987
Net cash provided by financing activities		9,094	53,633
Net change in cash and cash equivalents for period		(719)	(752)
Cash, cash equivalents, and restricted cash at beginning of period		6,999	7,751
Cash, cash equivalents, and restricted cash at end of period		6,280	6,999
Income taxes paid		20	10
Fair value of warrants issued to subordinated debt holders		1,278	1,939
Fair value of stock issued to a related party for guarantee fees		0	2,012
Fair value of warrants issued to lender for debt issuance costs		318	3,158
Fair value of stock issued to lender		0	1,335
Parent Company [Member]
Net loss		(46,420)	(107,758)
Share-based compensation		7,660	6,410
Depreciation		51	29
Debt related fees and amortization expense		782	1,776
Subsidiary portion of net losses		25,370	91,561
Gain on litigation		0	(1,400)
Warrants issued for working capital agreement		409	0
Prepaid expenses		608	(111)
Accounts payable		699	(90)
Accrued interest expense		785	778
Other liabilities		85	(4,625)
Other assets		(276)	(207)
Net cash provided by (used in) operating activities		(10,911)	(13,001)
Capital expenditures		(65)	(128)
Subsidiary advances, net		(9,707)	1,222
Net cash used in investing activities		(9,772)	1,094
Proceeds from the exercise of stock options		133	206
Proceeds from issuance of common stock in equity offering		21,718	11,987
Net cash provided by financing activities		21,851	12,193
Net change in cash and cash equivalents for period		1,168	286
Cash, cash equivalents, and restricted cash at beginning of period		286	0
Cash, cash equivalents, and restricted cash at end of period		1,454	286
Income taxes paid		7	7
Fair value of warrants issued to subordinated debt holders		1,278	1,939
Fair value of stock issued to a related party for guarantee fees		0	2,012
Fair value of warrants issued for capital expenditures		318	0
Fair value of warrants issued to lender for debt issuance costs		0	3,158
Fair value of stock issued to lender		$ 0	$ 1,335

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands

Feb. 08, 2023

Mar. 06, 2020

Mar. 25, 2024

Mar. 22, 2024

Jan. 01, 2024

Dec. 31, 2023

Jul. 01, 2023

Jan. 01, 2023

Dec. 31, 2022

Dec. 31, 2021

Mar. 14, 2021

Jan. 09, 2012

Jan. 06, 2012

Warrants and Rights Outstanding, Term (Year)

5 years 9 months 7 days

7 years 5 months 23 days

4 years 11 months 12 days

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 11.7

$ 15.92

$ 2.59

Line of Credit [Member] | Required Credit Agreement to Satisfy Units Redemption Obligation [Member]

Debt Instrument, Term (Year)

12 months

Line of Credit Facility, Maximum Borrowing Capacity

$ 111,000

PUPA Fifth Amendment [Member]

Preferred Units Issued Value

$ 111,000

AAFK [Member] | Warrants in Connection With Subordinated Notes [Member]

Warrants and Rights Outstanding, Term (Year)

2 years

2 years

2 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 0.01

$ 0.01

$ 0.01

Subsequent Event [Member] | AAFK [Member] | Warrants in Connection With Subordinated Notes [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

113

Warrants and Rights Outstanding, Term (Year)

2 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 0.01

Subordinated Notes [Member] | AAFK [Member]

Debt Instrument, Fee Amount

$ 2,500

$ 900

Subordinated Notes [Member] | Subsequent Event [Member]

Equity Financing

$ 25,000

Subordinated Notes 1 [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 90

$ 90

Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

90

Subordinated Notes 2 [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 250

$ 250

Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member]

Debt Instrument, Cash Extension Fee

$ 250

Reserve Liquidity Facility [Member] | Third Eye Capital [Member]

Debt Instrument, Term (Year)

1 year

Line of Credit Facility, Maximum Borrowing Capacity

$ 70,000

Reserve Liquidity Facility [Member] | Subsequent Event [Member] | Third Eye Capital [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 85,000

$ 85,000

Debt Instrument, Fee Amount

500

Amendment No 28 [Member] | Subsequent Event [Member] | Third Eye Capital [Member]

Debt Instrument, Fee Amount

$ 100

Note 16 - Liquidity (Details Te

Note 16 - Liquidity (Details Textual) - Third Eye Capital [Member] - Reserve Liquidity Facility [Member] - USD ($) $ in Millions	Mar. 25, 2024	Mar. 22, 2024	Mar. 14, 2021
Line of Credit Facility, Maximum Borrowing Capacity			$ 70
Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 85	$ 85